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ANALYSE COÛT EFFICACITÉ DU PONTAGE CORONARIEN À COEUR
BATTANT PAR RAPPORT AU PONTAGE AORTOCORONARIEN
CONVENTIONNEL
OBJECTIF: Estimer le rapport coût efficacité différentiel (ICER) d’un pontage coronarien
à coeur battant (PCACB) par rapport à un pontage aortocoronarien conventionnel (PACC)
pour le traitement des maladies coronariennes touchant plusieurs vaisseaux et par rapport à
l’angioplastie coronarienne (AC) pour les celles touchant un seul vaisseau.
MÉTHODES: Un modèle de Markov, basé sur des méta-analyses et des études de
cohortes, ainsi que des données d’utilité, ont été utilisés pour évaluer les gains d’années de
vie ajustées par la qualité (QALYr) et les coûts de traitement sur la durée de vie des patients.
Des ICERs, évalués selon les perspectives du système de santé, de l’institution et de la
société, ont été estimés par une analyse de sensibilité probabilistique, en utilisant des dollars
canadiens de 2004 et un taux d’actualisation de 3%.
RÉSULTATS: L’ICER du PCACB était de (-) 76 95O$/ÀLY par rapport au PACC avec
80% de probabilité qu’il soit inférieur à 50 000$/QALY. L’ICER de l’AC est de 44
151$/QALY par rapport au PCACB, avec toutefois 45% de probabilité qu’il soit supérieur à
50 0O0$/QALY. Les perspectives institutionnelles et sociétale ont donné des ICERs
similaires.
CONCLUSIONS: Pour les maladies touchant plusieurs vaisseaux, le PCACB est une
alternative coût efficace par rapport au PACC. Pour celles touchant un seul vaisseau, l’AC
semble être un traitement coût efficace par rapport au PCACB, bien que plusieurs
incertitudes demeurent.
Mots Clés: coût efficacité, analyse de décision, analyse de sensibilité probabilistique,
maladies coronariennes, pontage coronarien, pontage coronarien à coeur battant,
angioplastie coronarienne, Canada
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OFF-PUMP CORONARY ARTERY BYPASS VERSUS CONVENTIONAL ON
PUMP BYPASS OR PERCUTANEOUS CORONARY REVASCULARIZATION:
A COST-EFFECTIVENESS ANALYSIS
PURPOSE: To estimate the incremental cost-effectiveness of off-pump coronary artery
bypass (OPCAB) versus conventional coronary artery bypass (CCAB) for multi-vessel
coronary artery disease, and to estimate the incremental cost—effectiveness of OPCAB
versus percutaneous coronary intervention (PCI) for single-vessel disease.
METHODS: A Markov state transition model, based on meta-analyses and cohort trials,
was utihzed to evaluate outcomes over a lifetime. Utilities were obtained to estimate quality
adjusted life years gained (QALYs). Lifetime treatment costs were calculated adopting a
health system perspective in the base case analysis, and institutional and societal perspectives
in secondary analyses. Incremental cost-effectiveness ratios (ICERs) were estimated (2004
Canadian dollars) using probabilistic sensitivity analysis with a 3% discount rate.
RESULTS: In the base case analysis, OPCAB dominated CCAB for multi-vessel disease,
since it was more effective (+0.12 QALYs) and less costly (-9234$). The estimated ICER
was (-) 76950$ per QALY gained, and there was 80% probabihty that die ICER was below
50000$/QALY. For OPCAB versus PCI in single-vessel disease, PCI was more effective
and more cosdy than OPCAB, with an estimated ICER of 44151$/QALY; however, there
was 45% probability that the ICER would be greater than 50000$/QALY. ICERs were
similar from the institutional and societal perspective.
CONCLUSION: For multi-vessel disease, OPCAB appears to be a cost-saving alternative
to CCAB. For single-vessel disease, PCI may be a cost-effective alternative to OPCAB,
although significant uncertainty remains for the latter.
Keywords: cost-effectiveness, decision analysis, probabilistic sensitivity analysis, coronaiy
artery disease, coronary artery bypass surgery, off-pump, angioplasty, Canada
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1CHAPTER 1
INTRODUCTION
This chapter introduces readers ta the importance of cardiovascutar diseuse. Tt]e ctinicat
burden and economic b;trden associated with cardiovascutar diseuse is described, and
treatment options are e.pÏored.
1.1 Impact of Cardiovascular Disease Worldwide
No other cinical area brings as much attention as cardiovascular disease. According to the
2003 World Health Report an estimated 16.7 miffion, or nearly 30% of total global deaths,
resuit from the various forrns of cardiovascular disease including coronary artery disease
(CAD), many of which are preventable. 0f the 16.7 million deaths from cardiovascular
disease every year, 7.2 mDiion are due to ischemic heart disease and 5.5 million to
cerebrovascular disease (World Health Organization, 2003).
Cardiovascular disease is increasingly affecting people in their mid-life years, leading to
staggering estimates of healthy life lost. When healthy years are lost, the socioeconomic
development of nations and its communities is undermined
— whether in developed or
developing countries.
Until recendy, cardiovascular disease xvas considered the scourge of the rich “(7estern world’.
However, the World Health Organization reports that a similar pattern of cardiovascular
disease is emerging in developing countries. Today, about 8O% of cardiovascular deaths take
place in low and rniddle-incorne countries, and in terrns of absolute numbers, twice as rnany
of these deaths occurred in developing countries as in the developed world. By 2010,
cardiovascular disease is likely to be the leading cause of death in developing countries, and
along with the continuing toll secondary to communicable disease, this duo of diseases has
corne to be known as the “double burden” which caïls for a “double response”. (World
Health Organization, 2003)
21.2 Clinical and Economic Importance of Cardiovascular
Disease
In Canada, cardiovascular disease accounts for 36% of ail deaths and is the leading cause of
death and disability (Weilgosz 1999). While the cinical toil on Canadians directly attributable
to cardiovascular disease is higli, the economic toli is equaily devastating. Estimates from
1998 suggest that cardiovascular disease was the greatest sole contributor to direct cost of
iilness in Canada, accounting for l$% of health care system expenditures. Overail, the total
cost related to cardiovascular disease in Canada exceeds 18$ billion (Eisenberg 2005). The
enormity of this burden on the healthcare system — both cinical and economic — is unrivaled
by any other singular disease. This underscores the need for careful and constant exploration
of potential areas for improvement as even small changes will portend large shifts in cinical
and economic outcomes.
While many pathologic conditions affect the heart, the most common cause of
cardiovascular disease is coronary artery disease (CAD). The primary cause of coronary
artery disease is coronary atherosclerosis, which develops from subendothelial accumulation
of lipid and subsequent formation of fatty streak on the arterial surface. This process is
known to begin in childhood, and continues to progress at a rate determined by genetics,
age, gender, lifestyle choices (ie, smoking, diet) and accelerated by comorbities such as
diabetes, hypertension, and hyperlipidemia. By the third decade of life, fatty streaks are
evident in the aorta, cerebral arteries, and coronary arteries. The left anterior descending
coronary artery is often most susceptible to accumulation of fatty plaques that may impede
blood flow to the heart. The resulting ischemic coronary artery disease may be characterized
by silent or symptomatic angina, myocardial infarction, or death.
1.3 Treatment Options
Three main approaches exist for the management of CAD. The least invasive option is
medical management, which attempts to control symptoms and maximize survival through
the use of drug therapies. for patients with CAD who are refractory to medical
management, die alternative may be to restore blood flow to the jeopardized areas of heart
3muscle via interventional cardiac revascularization, tvpically though either surgical coronary
artel-v bypass grafting (CABG) or non-surgïcal percutaneous coronary intervention (PCI).
Treatment choice is based on a variety of factors, including patient age, comorbidities, extent
of disease (i.e., number and location of affected coronary arteries), and disease severity.
1.3.1 Conventional On-Pump Cofonary Artery Bypass Graft Surgery
(CCAB)
Surgical cardiac revascularization aims to restore healthy blood flow to the heart muscle by
bypassing (or ‘grafting’) the obstructed coronary vessels with a segment of blood vessel
hanrested from elsewhere in the body. Surgical bypass grafting may be performed on a single
vessel or on multiple vessels that are affected by CAD. Conventionally, surgical coronary
artery bypass grafting is performed with the use of pharmacologic cardioplegia to stop the
beating heart, and with the support of the cardiopulmonarv bypass pump (CPB) to maintain
blood flow externally for the patient throughout surgery. The CPB enables the surgeon to
operate on an arrested heart on a stationary bloodless operating field with clear exposure of
the major coronary branches. Exposure of blood to the CPB circuit may damage blood ceils
and increase die risk of complications such as bleeding, stroke, myocardial infarction, renal
dysfunction, and neurocognitive dysfunction (Ascione 2000, Cheng 2005, Gullelmos 1999,
Lee 2003).
Conventional CABG has been shown to improve sunrival and quality of life in certain
patient groups ÇI’aggart 2002). As a result, CABG is currendy one of the most commonly
performed major operations in the industrialized world. In the year 2000, approximately
25,000 CABG surgeries were performed annually in Canada. In comparison, nearly 500,000
CABG surgeries were performed in the year 2000 in die US, haif of die worldwide total of
over I million (Eisenberg 2005, Taggart 2002). These numbers are expected continually to
tise since as many as forty percent of Canadians will develop some form of heart disease in
their lifetime.
Since it is a high volume procedure requiring intense surgical and perioperative care, widi a
risk of adverse events that can significandy impact quality of life, CABG remains one of die
4most studied areas of health care (Ghali 2003). Despïte the complexity of the surgery and the
nature of cardïopulmonary bypass, the mortality associated with CABG in the current era is
very low. Ghall and colleagues reported a favourable national trend of decreasing observed
and risk-adjusted rates of death after CABG from 1992 to 2001. The 40% relative dedine in
adjusted death rates over this period from 3.5% (95%CI, 3.2% to 3.8%) to 2.0% (95%CI,
l.$% to 2.3%) was observed despite increasing baseline patient risk due to comorbidities in
patients presenting for CABG (Ghali 2003). Over the past decade in Canada, patients
selected for CABG are, on average, increasingly older and sicker and their cases more
complex, and yet they are more likely to survive the procedure (Ghali 1999, Ghali 1998,
Hannan 1994, Ivanov 1998, Peterson 1994).
Nevertheless, the reductions in mortality achieved by advances in technologies and
techniques over the past four decades have stabilized in the last few years, despite the
continuous quest for further reductions in mortality. Recent attention has focused on the
role of the cardiopulmonary bypass pump in maintaining this impasse in further mortality
risk reduction. While use of the CPB pump provides technical advantages and convenience
for the surgeon to operate on the bloodless and motionless surgical field, blood exposure to
the bypass circuit resuits in a cascade of physiologic responses that have been implicated in
contributing to the risk of adverse events, including death, stroke, coagulation disorders, and
cognitive decine. 0f these, death and stroke are the most notorious CPB-associated adverse
events (Ascione 2000, Diegeler 2000, Cheng 2005).
Excess risks associated with CPB exposure may be particularly concerning with increased
age. As a greater proportion of the population survives into later decades of life, more
septaugenarians and octogenarians are undergoing CABG and the added risks due to CPB
exposure are most relevant in this group. The balance of benefits and risks in this population
require careful consideration when deciding whether to intervene surgically, or opt for
alternative management of CAD (Ghali 2003, Ghali 1999).
In addition to the notable increased average age of patients undergoing CABG, patients are
of increasingly higher risk compared with earlier decades. As the technology and sIdlls for
performing CABG have progressed, patients with risk factors (concomitant pulmonaiy
5disease, renal disease, hepatic disease, history of stroke) who in previous years would have
foregone surgery due to excess risk are now undergoing multi-vessel surgery (Ivanov 1998).
Concerns about the adverse effects of cardiopulmonary bypass and the changing
demographics of the surgical population have spurred exploration of alternative methods for
revascularizing coronary arteries. Two key interventions have been developed in response to
this pressure to find safer alternatives: off-pump coronary artery bypass surgery (OPCAB)
and percutaneous coronary intervention (PCI).
1.3.2 Off-Pump Coronary Artery Bypass Surgery (OPCAB)
Off-pump coronary artery bypass (OPCAB) surgery lias become a widely lauded innovation
in heahhcare, for the second time. Before the development of the early cardiopulmonary
bypass pump in 1954, surgery was attempted on the beating heart without much success.
The eventual development of cardiopulmonary bypass was lauded as a major milestone in
medicine, as it allowed the surgeon to divert blood flow away from the heart and to create a
stiil surgical field by stopping the beating muscle through pharmacologic cardioplegia.
However, in developing countries, the extremely limited available CPB resources provided
motivation to continue to pursue off-pump techniques (Buffolo 2006, Favaloro 1998,
Favaloro 196$, Westaby 1997).
Beating heart surgery, or off-pump coronary artery bypass (OPCAB), allows surgical
revascularization to lie performed without the CPB, and may be a less invasive alternative to
surgical CABG. Surgical access in OPCAB is gained via median full sternotomy or lateral
mini-thoracotomy (also known as minimally invasive direct coronary artery bypass,
MIDCAB). The beating heart is retracted and snares are placed around the target coronary
vessel to create a surgical field for revascularization. With the aid of local immobilization
technology, a bypass graft is anastomosed to the occluded artery while the heart remains
pumping.
Minimally invasive coronary artery bypass (MIDCAB) was developed to help reduce surgical
trauma and shorten hospital stay after coronary revascularizadon, and is a subset of OPCAB
6since it is performed on the beating heart. Surgeons performing MIDCAB attempt to work
on the heart through several small incisions. However, this technique is less common than
OPCAB since patient’s morphology must be suitable and since working on a beating heart
through a small hole accessed between the ribs is difficuit.
While avoiding the use of the bypass pump may present advantages for the patient, it
presents a novel set of challenges for the surgeon. Performing delicate anastomoses on
moving surgical field requires advanced technical expertise. Continued blood flow through
the arteries of the heart may hamper the visual field and suture placement, and temporary
interruption to the target artery may increase heart muscle irritability and arrhythmias
(Puskas 2004, Puskas 2005). Visualization of posterior arterial branches through anterior
dispiacement of the heart may dangerously impair cardiac output and hemodynamic stability.
Due to heightened challenges, patients with difficult morphology, intramyocardial target
coronary artery, or diffuse disease may be ineligible for die procedure (Borst 1999).
Development of newer stabilizing devices has direcdy facilitated the evolution and uptake of
OPCAB into the mainstream. Availability of these devices has now made avoidance of
cardiopulmonary bypass a realistic proposition for many patients with increasingly difficuit
morphology, including those with multi-vessel disease.
1.3.3 Percutaneous Coronary Intervention (PCI)
Percutaneous coronary intervention (PCi) is a medical procedure in which a balloon is used
to open narrowed or blocked coronary arteries. It is flot considered to be a type of surgery.
Percutaneous coronary intervention can also be referred to as percutaneous transluminal
coronary angioplasty (PTCA). In almost ail cases, a device called a stent made of steel mesh
or expandable wire is also placed at the site of narrowing or blockage in order to keep the
artery open.
For patients with single vessel CAD affecting the lefr anterior descending coronary artery,
the two main established treatment procedures are CABG and PCI (sucli as PTCA with or
without stenting). Both of these interventions are effective for reducing symptoms, although
7CABG is more invasive and more cosdy than PCI over the short term, and reduces the need
for reintervention over the mid-term and the longterm (Reeves 2004). In the current era,
PCI with stendng has become the most widely used treatment for isolated stenosis of single
vessel CAD because of ïts comparable short term outcomes relative to the more invasive
surgical options. Nevertheless, the rationale for the more rapidly increasing popularity of
PCI relative to OPCAB has recendy been questioned, since the resuits of conventional
surgical bypass remain more robust than PCI over time as manifested by signifïcantly
reduced reintenrention rates, and the possibility of improved survival (Boodhwani 2006,
Hueb 2004, Mercado 2005, Pocock 1995, Rodriguez 2001, SoS 2002, Serruys 2001).
Given that surgical revascularization may have durable advantages, and given that patients
with isolated left anterior descending CAD have coronary anatomy particularly suitable to
off-pump technique, OPCAB through full sternomy or mini-thoracotomy (MIDCAB) has
become of particular interest for this lower risk patient population. Recendy, OPCAB is
emerging as the most relevant direct competitor to PCI for the management of single or
uncomplicated double-vessel CAD.
$CHAPTER 2
ECONOMIC ANALYSES 0F 0FF-PUMP VERSUS
ON-PUMP CORONARY ARTERY BYPASS GRAFT
SURGERY
- A LITERATURE REVIEW
2.1 Context
Against a background of rising costs in healthcare, there has been an upsurge in interest in
health economics. This is evidenced by an increasing number of health economists and an
exponentially expanding volume of published economic studies (McDonald 2001; Meltzer
2002; Pritchard 199$).
Impetus for this growth is related to the increasingiy large budget impact for relatively small
margins of benefit provided by new heaith technologies compared with older standards of
care. The science of economic analysis and health technology has arisen out of a need to
assess and evaluate whether new technologies and techniques should be taken up, given that
not ail of them can be afforded (Fenwick 2004, Gold 1996, Hoch 2006, Scott 2005).
Health economic analysis (HEA) is a formai set of quantitative measures that assess the
resources utilized and the expected outcomes when comparing two or more treatments
(D rummond 1997). The main purpose of an economic evaluation is to inform judgments
about “value per dollar spent” for a given set of alternative interventions or programs.
Economic evaluations can help inform priority-setting by identifying interventions that are
worth providing and those that are flot (CADTH 2006, Hoch 2006).
In publicly funded health care systems, as in ail settings, the limited availability of resources
means that not ail avaïlable interventions can be provided to meet every want and need.
Indeed, the reality of limited resources in healthcare suggests that even interventions with
proven efficacy cannot be provided in aIl circumstances. Therefore, choices must be made
among effective health care interventions, and every choice entails a trade-off (Rawiins
92004). The decision to fund one intervention means that those same resources cannot be
committed elsewhere, and so others cannot be funded. This concept lias been termed
‘opportunity cost’, and is central to the impetus for economic analysis. The opportunity cost
of funding the chosen intervention should be interpreted as the health benefits that could
have been derived from funding the next best alternative (CADTH 2006).
Whule economic analyses are becoming more plentiful, the fleld of health economics is stiil
evolving. A number of reguiatory and funding agencies (NICE in the UK, PBAC in
Australia, CED/OHTAC in Ontario) require formai economic analyses to inform decision
maldng for selected technologies; however, there are inconsistencies amongst these agencies
regarding how economic analyses should be used to inform decisions. A number of decision
makers have suggested that economic analyses are crucial, but that most health professionals
and administrators remain unfamiliar with their methodology and appropriate interpretation.
These limitations are recognized by the growing community of health economists, who
continuafly aim for improved metliods to communicate die results of economic analyses in
order to better meet decision makers’ needs.
2.2 Economic Analyses of Off-Pump Coronary Revascularization
Renewed interest in off-pump coronary artery bypass grafting (OPCAB) as an ïnnovative
alternative to conventional on-pump coronary artery bypass surgery (CCAB) raises
important questions about whether the dinical outcomes warrant the resources required to
adopt this new technique for surgical revascularization.
The cost of OPCAB compared with CCAB lias been addressed in a number of publications.
While a number of these publications have been non-experimental narratives discussing
issues related to resource utilization, there have also been a number of economic analyses
conducted alongside randomized controiled triais or retrospective comparisons of registry
data (Gray 2003).
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2.3 Rationale
A feview of economic analyses was conducted very early in the uptake of OPCAB in the
developed world (Gray 2003). In this review, Gray and colleagues summarized and critically
evaluated the existing evidence regarding costs and cost-effectiveness of OPCAB. However,
there lias been a dramatic increase in published literature related to OPCAB in recent years.
Since there have been no recent systematic reviews of economic analyses of OPCAB versus
CCAB or OPCAB versus PCI, a comprehensive systematic review of the literature was
undertaken to explore the range of economic impacts reported for OPCAB relative to
conventional forms of revascularization. This review will set the context for our economic
analysis, which should be interpreted in light of the existing literature.
2.4 Methods
A comprehensive search was undertaken in accordance with Cochrane Collaboration
recommendations to identify ah English language, published or unpublished studies of
OPCAB versus CCAB or PCI that reported costs or cost-effectiveness. MEDLINE,
Cochrane CENTRAL, EMBASE, Current Contents, DARE, NEED, INAHTA databases
were searched from the date of their inception to July 2006. Search terms included variants
of off’-pztmp, rninirnat/y invasive, beating hear4 coronay artey bjpass, cos4 econo,nù, and cost-f7ctiveness.
Tangential electronic exploration of related articles and hand searches of bibliographies,
scientific meeting abstracts, and related journals were also performed: Appendix A outlines
the Medline search strategy.
2.4.1 Inclusion Criteria
Studies were included if they met eacli of the following: (1) adult patients with single or
multiple vessel coronary artery disease suitable for revascularization with OPCAB; (2)
randomized or non-randomized comparison of OPCAB with CCAB or PCI (with or
without stenting); (3) reporting at least one pertinent economic outcome such as in-hospital
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costs and/or costs after longer term follow-up. Hybrid (i.e. OPCAB plus PCI combined
procedure) studies were excluded.
2.4.2 Data Extraction
Two authors independently identified trials for inclusion and extracted information on study
design and setting, and extracted cost and cost-effectiveness data. Disagreements were
resolved by consensus.
2.4.3 Endpoints
Endpoints of interest were direct costs (fixed and variable), indirect costs, total costs, and
incremental cost-effectiveness ratios (ICERs) for any available time horizon, including in
hospital and longer term follow-up.
2.5 Resuits
Appendix B oudines the results of the systematic search. Twenty-three articles publlshed
between 1997 and 2006 were included in die review. A significant number of studies were
not included since they did ont report costs, but only reported other indicators of resource
utilization such as length of stay. Nineteen of the included studies compared costs of
OPCAB with those of CCAB (5 randomized trials; 14 non-randomized analyses). Appendix
C and Appendix D outline the results for OPCAB (or MIDCAB) versus CCAB randomized
and non-randomized studies, respectively.
Four studies reported comparative costs for OPCAB or MIDCAB versus PCI (3
randomized swdies; I non-randomized analysis). Appendix E outlines the results of
included studies of OPCAB versus PCI.
Ail of the studies reported comparative costs for in-hospital, 30 day, or I year follow-up. A
total of four studies conducted a formal economic analysis (Appendix F), and reported
incremental cost-effectiveness ratios (2 OPCAB versus CCAB; 2 OPCAB versus PCI)
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For studies of OPCAB versus CCAB reporting costs, ail studies except for one reported that
OPCAB vas significandy less cosdy than CCAB for in-hospital direct costs and I year direct
costs. The range of cost reductions was from li% to 5Q% for in hospital costs, and from
l2% to 34% for total costs up to I year. Randomized and non-randomized studies reported
similar proportions of cost reductions.
For studies of OCPAB versus PCI, ail studies showed that OPCAB was more expensive
than PCI. The reported reduction in hospital costs for PCI relative to OPCAB ranged from
20 to 48%. At one year, the estimated difference in costs was 26 to 33%.
In the formai cost-effectiveness analyses, the range of ICERS reported for OPCAB relative
to CCAB was 140000$/QALY to 184000$/QALY. While the ICERS differed in magnitude,
they are consistent in suggesting that OPCAB costs less and is also slightly less effective at I
year foilow-up. For OPCAB versus PCI, the ICERS varied between the two trials, from (-)
98000$/QALY to 45000$/QALY. Due to differences in methods of collecting and
reporting cost data across these trials, pooied anaiysis xvas not possible for meta-anaiysis of
costs or cost-effectiveness.
With the exception of the randomized triais in which formai economic analyses were
performed, most studies did not provide adequate detail of costing methodology to critically
evaiuate the quality. Cost swdies that were non-randomized studies were generally
retrospective reviews of prospectively coilected registry data or chart reviews. These studies
suffer from the limitations inherent in observadonal studies of nonrandomized groups.
Patients seiected for OPCAB are likely to be different from those selected for CCAB, and
this has been shown by examination of basehne characteristic differences amongst non
randomized comparisons of OPCAB versus CCAB (Puskas 2005). Despite attempts to
control for imbalances by stratification, case-matcbing, or propensity scoring, some of these
studies used methods that were based on non-validated risk scoring systems. Even when
validated risk scoring systems were used, there is no guarantee that ail baseline imbalances
have been accounted for appropriately, and the impact of remaining differences on resource
utilization wiil flot be known. With respect to proving difference between OPCAB versus
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CCAB resource utilization for a given patient population, these studies should be interpreted
with caution. Nevertheless, these studies can be considered useful for gaining insight into
real-world differences in resource utilization that may be the resuit of differential resource
requirements for each of the respective types of surgery on the background of differential
patient selection for OPCAB versus CCAB.
2.6 Discussion
Most published comparative analyses of OPCAB and CCAB have reported that OPCAB is
less cosdy than CCAB over the short and mid-term. In hospital and I year estimates of
difference in cost were relatively uniform, ranging from 11 to 5O% lesser cost with OPCAB
over the short term and l2% to 34% in the mid-term. While the direction of effect was
similar across trials, the magnitude of difference varied, and may be attributable to
differences in cost definitions and local practices. Trials of OPCAB versus PCI uniformly
suggest that OPCAB is more costly by 20 to 4$% over the short and longterm. However,
most of the data evaluating economic outcomes for OPCAB were non-randomized studies,
subject to selection bias. Incremental cost-effectiveness analyses ranged widely, especiallv for
OPCAB versus PCI.
0f the economic analyses conducted alongside randomized trials, each was conducted in the
United States, with a perspective that primarily reflects its unique health system structure,
which may be less generalizable to other countries. In addition, these economic analyses
estimated the cost-effectiveness or cost-utilitv up to a maximum of one year. Since important
differences may develop after one year, perhaps due to changes in requirement for
revascularization over the longer term and loss of QALY due to differences in risk of stroke
or cognitive decine, this timeframe is insufficient to adequately estimate cost-effectiveness
over the duration of time that ïs of greatest interest
— ie, the timeframe that is relevant to
sufficiently measure the impact of differences in need for revascularization and longterm
disability due to stroke or cognitive decine. In none of the economic analyses published to
date were the results modeled to provide estimates beyond one year.
HGiven the range of estimates of costs, and the relative lack of formai economic evaluation
over relevant time horizons, further studies should be encouraged to better delineate the
cost-effectiveness of OPCAB versus CCAB, and in particular, OPCAB versus PCI. Future
studies repordng economic outcomes should follow economic guidelines (CADTH 2006),
and should provide more explicit detail regarding costs and their measurement.
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CHAPTER 3
PURPOSE & OBJECTIVES
This chapter states the pitipose ana’ objictives oft/e economic ana/ysis.
3.1 Purpose
The overarcHng purpose of this economic analysis was to estimate the cost-effectiveness of
choosing off-pump coronary artery bypass (OPCAB) rather than conventional forms of
revascularization including on-pump surgical coronary artery bypass (CCAB) or
percutaneous coronary intervention (PCI) across a variety of perspectives and patient risk
groups.
Decision analysis was undertaken to assess the following competing alternatives for
interventional treatment of CAD:
i) OPCAB versus CCAB in average-risk and bigh-risk patients
ii) OPCAB versus PCI in lower-risk patients
Three interventions were evaluated in this analysis since OPCAB is an innovative contender
to conventional revascularization for the full spectrum of patient risk groups, while the
relevant comparator is dependent upon patient risk. Specifically, CCAB ïs the relevant
comparator for average-risk and high-risk patients only and PCI is the relevant comparator
for low-risk groups only. In this context, average-risk patients are defined as patients with
multivessel coronary artery disease who are eligible for surgical revascctlarization, but who do
not have major comorbidities considered to place them at high risk. High risk patients are
deflned as those patients with multivessel disease who have concomitant characreristics or
comorbidities known to place them at increased perioperative risk, such as advanced age
(>70 years), or preexisting renal failure, chronic obstructive pulmonary disease,
atheromatous aorta, left ventricular dysfunction, diabetes, redo or urgent revascularization,
or a high preoperative dinical risk (ie, Euroscore 5 or greater). Low risk patients are defined
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as those with single-vessel disease who are eligible for surgical bypass or percutaneous
coronary revascularization.
Therefore, to address the overarching purpose of defining the cost-effectiveness of OPCAB
relative to conventional forms of revascularization (CCAB for higher risk patients, and PCI
for lower risk patients), two decision trees were constructed for two different cohorts of
patients. One decision tree was constructed for average-risk patients and high risk patients
undergoing OPCAB or CCAB, and a separate decision tree was constructed for lower-risk
patients undergoing OPCAB or PCI. A modified tree structure was required for OPCAB
versus PCI, since the latter lias a different array of possible in-hospital outcomes (i.e.,
neurocognitive outcomes, transfusions, arrhytlimias, renal dysfunction were not reported in
most OPCAB vs. PCI trials) and longer term risks (i.e., angina recurrence was better
characterized for OPCAB vs. PCI than for OPCAB vs. CCAB trials).
3.2 Objectives for OPCAB versus CCAB
3.21 Primary Base Case Analysis
(I) To estimate from the perspective of the Canadian publicly funded health care system, the
incremental lifetime cost per quality-adjusted life year (QALY) of performing OPCAB
instead of CCAB in average-risk patients who are eligible for surgical revascularization of
CAD.
32.2 Secondary Analyses
(1) To estimate the incremental cost per QALY of OPCAB versus CCAB in specifled high
risk patient groups, including advanced age (>70 years), or preexisting renal failure, chronic
obstructive pulmonary disease, atheromatous aorta, left ventricular dysfunction, diabetes,
redo or urgent revascularization, or a higli preoperative cinical risk (ie, Euroscore 5 or
greater).
(2) To estimate the incremental cost per QALY for OCPAB versus CCAB from other
perspectives, includïng die institutional perspective, and the societal perspective.
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(3) To determine the robustness of the cost-effectiveness estimates over a range of plausible
values for key assumptions made through one-way, two-way, and probabilistic sensitivity
analyses.
3.3 Objectives for OPCAB versus PCI
3.3.1 Primaq Base Case Analysis
To estimate from the perspective of the Canadian publicly funded health care system the
lifetime incremental cost per QALY of performing OPCAB instead of PCI in low-risk
patients with CAD who are eligible for percutaneous coronary revascularization (PCI).
3.3.2 Secondaiy Analyses
(1) To estimate the incremental cost per QALY for OCPAB versus PCI in lower-risk
patients from other perspectives, including die institutional perspective, and the societal
perspective.
(2) To determine the robustness of die cost-effectiveness estimates over a range of plausible
values for key assumptions made through one-way, two-way, and probabilistic sensitivity
analyses.
‘s
CHAPTER4
METHODS
Titis chapterpresents the rnethodology used to conduct a cost-ectiveness anaysisfor O?AB versus CC4B
and OPCAB versus PCI. The perspective, data sources, and ana’ytic rnethods are presented. The chapter
ctoses with a description ofptannedprirnay and secondciy anayses.
4.1 Study Design Overview
This cost-effectiveness analysis was conducted in accordance with the state-of-the-art
economic evaluation guidelines recendy released by the Canadian Agency for Drugs and
Technologies in Health (CADTH 2006).
The primary base case analysis was defined as the cost per quality-adjusted life years
($/QALY) from the perspective of the Canadian heahhcare system. In Canada, the vlinistry
of Health administers most health care resources, and therefore, the healthcare system
perspective in Canada is represented by the provincial ?vIinistry of Health. Whule this analysis
was conducted in an Ontario hospital, it was designed to be representative of any provincial
ministry of health across Canada.
Figure 1 presents an overview of the study design that was followed for this cost
effectiveness analysis. This study vas designed as a cost-utility analysis hitherto referred to
as a cost-effectiveness analysis since cost-utility is an extension of cost-effectiveness),
drawing from the cinical resuits of a series of meta-analyses conducted by our team and
from micro-level costs available at our institution supplemented by published costs.
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What is the role ofOPCAB in
today’ s health care environment?
Meta-Analysis of OPCAB versus Meta-Analysis of OPCAB versus
CCAB RCTs in Average Risk PCI in Low-Risk Patients
Patients
4r
___________________________
Meta-Analysis ofRCTs and nRCTs
for OPCAB versus CCAB in High Create OPCAB versus PCI Decision
Risk Patients Mode!
‘3r
Create OPCAB vCCAB
Measure Cost ofOPCAB, CCAB, and PCI
from LHSC Accounting Databases
Ascertain Additional Estimates of Resource Utilization
and Utilities from other Published Sources
Perform OPCAB versus CCAB Cost- Perforrn OPCAB versus PCI Cost
Effectiveness Analysis for Average Risk Effectiveness Analysis for Low-Risk Patients
Patients
_________ __ __ __ _ __ __ _ __ __ __ _____
1 j
Perform OPCAB versus
CCAB Cost-Effectiveness Report and Interpret
Analysis for High Risk Resuits across the
Subgroups Risk Spectrum of
CAD patients. Make
Recommendations
Figure 1: Study Design Overview
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4.2 Decision Tree for OPCAB versus CCAB in Average-Risk
Patients
Using Treeage (DATA 5.0, ©Treeage Software, mc, Williamstown, MA), a decision analysis
model was constructed to assess clinical outcomes and costs of OPCAB versus CCAB. The
target group for the baseline analysis was a hypothetical cohort of average-risk patients
(mean 2.7 target vessels, 22% female, 25% diabetic, average ejection fraction 0.60) for
revascularization who were 63 vears of age and who were eligible for surgical
revascularization of multi-vessel CAD. The demographics of the hypothetical cohort group
matched those of the summary patient characteristics in the meta-anal sis from which
cinical probabilities were derived for this analysis.
4.2.1 Analytic Model
An expected-value decision-analysis model was constructed to calculate the present value of
the expected lifetime costs per QALY gained by choosing to perform cardiac surgical
revascularization through OPCAB instead of CCAB. A cornpressed representation of the
decision tree is found in Figure 2, and the full decision tree is displayed in the Appendix G.
[1
[1
Initial OPCAB
t O[+jf NCD
f,,.- O [+]
OPCAB j Stroke
OPCAB dS
Clone 1: CAB Procedure
Figure 2: Compressed Decision Tree Outlining the 5-State Markov Model for
OPCAB versus CCAB
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The decision node for the base case posed the question: What is the best surgical strategy for
managing average-risk patients who present with multi-vessel CAD and is ehgible for either
conventional on-pump coronary artery bypass (CCAB) or off-pump coronary artery bypass
(OPCAB)? A Markov model was used to simulate the initial post-operative cinical course
(up to 30 days) as well as mid-term (1-2 years) and long-term (3 to 20 years) outcomes
associated with each treatment strategy. The five health states in the Markov model were as
follows: initial OPCAB, neurocognitive dysfunction (NCD), stroke, post-procedure
(uncompllcated by NCD, stroke, or death), and death.
After passing through the initial risk of immediate perioperative complications myocardial
infarction, angina recurrence, atrial fibrillation, transfusion, renal fallure, respiratory
infection, rethoracotomy for bleeding, need for inotropes or intra-aortic balloon pump
(IABP), and wound complications, the patient cohort moved to the initial health state (ie,
‘initial OPCAB’ for the off-pump surgery branch,) where the 30 day and I to 2 year risk of
stroke, reintenrention, neurocognitive dysfunction, and death was evaluated. For both
treatment options, the tree diverged to evaluate the range of potential successive cinical
outcomes and complications represented bv chance nodes within each health state of the
v1arkov model. For example, in Appendix H, one branch of the first Markov health state
(‘Initial OPCAB’) is fully expanded to reveal the set of potential outcomes that patients in
this health-state may experience within the first year post-procedure.
Within each Markov state, probabilities for the risk of stroke, NCD, reintervention and
death were applied. Patients experiencing one of these events transitioned at the end of the
cycle to the health state that represented that condition. For example, patients experiencing
reintervention for ischemia were assumed to undergo surgical revascularization and
experienced an immediate set of procedure-specific set of risks (refer to Appendix I,
Reintervention subtree) and were re-entered into the ‘initial post-OPCAB’ state at the next
Markov cycle. Patients who experienced stroke, NCD, or death were transitioned to the
‘stroke’, ‘NCD’, or ‘death’ health states, respectively, at the next cycle. Patients who
experienced no reintervention, stroke, NCD, or death during the cycle were transitioned to
the ‘post-procedure’ state for the next cycle.
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A one-year cycle time was used, and patients moved through Bye transition health states
based on probabilities from the literature until they reached the absorbing state of death
related to the procedure or from a competing cause based on disease-specific survival curves
from the literature (Weintraub 2003, Bradshaw 2002), or until 20 years (20 Markov cycles)
had passed. Since most 63 year old individuals with multi-vessel CAD undergoing CABG
wiil have a Ufe expectancy less than 20 years, this model was expected to approximate
lifetime costs.
Wbule the Markov health states and subtrees for OPCAB and CCAB are identical in
structure, the probabilities of complications differed between strategies.
4.2.2 Costs
Appendix J outlines the costs for the OPCAB versus CCAB decision model. Costs for
OPCAB or CCAB procedures and complications were based on hospital costs derived from
our institutional activity-based cost accounting system which includes patient level data for
selected services, supplies including pharmacy, blood work, radiology procedures, nuclear
medicine investigations, and specific procedures such as coronary artery bypass graft surgery,
percutaneous transiuminal coronary angioplasty, coronary angiogram, and catheterization. In
addition, non-microcosted data including worMoad units assigned to each patient for
overhead costs such as salaries and benefits for ail cinical, clerical and management
personnel, general supplies and sundries, depreciation of equipment used at the functional
centre, leasing costs, and accruals were included in the total estimated cost per patient. For
physician fees not paid direcdy by the hospital, professional fees outlined in die Ontario fee
Schedule were added to the total cost per patient.
A cohort of 1026 consecutive patients from our institution (London Health Sciences Centre
in Ontario, Canada) who underwent on-pump CABG during the 2003/2004 fiscal year was
used to calculate the mean cost of CCAB, and a cohort of 135 consecutive patients from our
institution undergoing off-pump CABG during 2002 to 2004 was used to estimate the mean
cost of OPCAB. Data from our institutional case-costing system was supplemented by an
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additional database developed at our institution to characterize off-pump bvpass patients.
Patients undergoing dual procedures (i.e., valve repair plus CABG) and those undergoing
robotic surgery were excluded from the cohort analysis. Costs associated with the surgery
theatre time, supplies (including the stabilizer technology and disposables for OPCAB), and
length of stay including overhead costs and depreciation, plus the cost of professional fees
paid by the Ivllnistry of Health of Ontario, were included in the cost estimates. It was
assumed that perfusionists’ fees should also be added since a perfusionist is generally on
stand-by throughout OPCAB in case of the need for cross over to on-pump CABG.
Physicians’ fees and costs associated with follow-up were derived from the Ontario Schedule
ofBenefits (OHIP 2000).
For costs of postoperative complications, data xvas used from our institutional cohort when
possible. When reliable unit costs were flot available from our institution, we consulted the
Ontario Case Costing Project (Ontario 1996) which characterizes costs of hospitalization by
case-mix group or principal procedure, or failing that, the published literature for relevant
Canadian (preferentially) or international estimates. Recognizing that published estimates of
complications will usually include the base cost of hospitalization, and recognizing that
when the incremental cost attributable to a complication is reported from other centres’
experiences, these costs will not be valid to add direcdy to our base estimate of hospital cost.
Therefore, the ratio of the cost for CABG patients experiencing specific complications
divided by that of uncomplicated CABG was applied to the unit cost for uncomplicated
CABG from our institution. This approach was considered justified in order to avoid double
counting which can occur when the base cost of hospitalization is included in pubhshed
estimates of total cost of complications. Since no information vas available for the
difference between groups in costs related to medications after hospital discharge, we did
flot apply costs for medications outside of die hospital setting.
Costs associated with the surgery theatre time, supplies (including the stabilizer technology
and disposables for OPCAB), and length of stay including overhead costs and depreciation,
plus the cost of professional fees paid by die Ministry of Health of Ontario, were included in
die total cost estimates.
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When stochastic data was available, the 95% confidence interval vas used to deRme the
range. Otherwise, the costs were made to vary by about ± SO% (or some other percentage
based on local professional opinion solicited informally from our cardiac surgical team). in
sensitivity analyses. Ail costs were converted to 2004 Canadian dollars, using the Consumer
Price Index for Health and Personal Care for Ontario of Statistic Canada (Statistics Canada
2006). In the base case analysis, a discount rate of 3% was used for future benefits and cots
occurring beyomd one year (Gold 1996; Garber 1996), and semsitivity analyses using discount
rates of 0% to 5% were conducted (CADTH 2006).
4.2.3 Perspective
For the base case amalysis, costs relevant to the ministry of health were included. Secondary
analysis was undertaken to consider the societal perspective, wherein additional costs related
to estimated productivity loss were added to the total cost of follow-up. For productivitv
loss, the estimated duration of productive time lost due to illness was multiplied by the
median income for an individual in the year 2004 as published b>’ Statistics Canada as
oudined in Appendïx K (Statistics Canada 2005). Since the specific duration of time an
individual is advised to remain off work is subject to individual physician discretiom and
patient characteristics, a range was used in subsequent sensitivity analyses. Since OPCAB bas
not been definitively shown to reduce time away from work, the productivity loss associated
with the procedure vas estimated to be die same as that for CCAB (Cheng 2005). Applying
an estimate of productivity loss to alI patients may overestimate costs, but minimizes the risk
ofvaluimg employed patients differendy than umemployed patients.
The institutional perspective was also estimated, wherein costs irrelevant to the institution
were eiminated including costs due to lost productivity, transfusions (paid for bv Canadian
Blood Services rather than by the institution), professional fees paid by the ministry of
health, and ambulatory (non-hospital) follow-up costs. Appendix L outlines the types of
costs considered for each perspective analyzed.
4.2.4 Probabifities
Appendix M outlines die probabilities for cinical events and their sources. Probabilities and
95% confidence intervals for cinical outcomes and complications were derived from a
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comprehensive meta-analysis of 37 randomized controlled trials direcdy comparing OPCAB
to CCAB, involving 3369 patients (Cheng 2005). This meta-analysis provided probabilities
for cinical outcomes in the immediate post-operative period, and up to 2 years post
operatively. Ufe expectancy and rates of ail-cause mortality unrelated to OCAB or CCAB
procedures were derived from disease-specific sunrival cunres (Weintraub 2003, Bradshaw
2002).
Since there is a known inherent risk, albeit small, of emergency cross-over from off-pump
surgery to on-pump surgery due to difficuit morphology or other technical issues arising
after chest entry that may preclude off-pump revascularization, this risk was built into the
model by averaging the cost and excess risk of complications of cross-overs within the initial
OPCAB health state and at each transition probability for repeat revascularization. This was
in accordance with the data provïded by the meta-analysis of OPCAB versus CCAB,
whereby die reported crossover rate for OPCAB to CCAB was 6% (Cheng 2005).
Probabilities within the initial OPCAB or initial CCAB Markov health state represented early
(in hospital) outcomes in detail applied as a probabilitv and cost equation to the cohort prior
to entry to the Markov model (see cost of immediate perioperative complications in
Appendix J), followed by mid-term outcomes (up to 2 years), and long-term outcomes
(beyond 2 years and for the remainder projected lifespan or up to 20 years post-operatively,
whichever occurred first).
In general, when assumptions were necessary, they were made to err on the side of
conservatism for cost-effectiveness of die innovative strategy, OPCAB, relative to the
conventional strategv. We assumed patients requiring reintenention for ischemïa would
undergo surgical revascularization, rather than with percutaneous coronary intervention. In
addition, we assumed that angina recurrence was adequately refiected in the probability for
reintervention. Since randomized trials provided data for clinical events only up to 2 years, it
was assumed that there would be no continued differences in probabilities between OPCAB
and CCAB for years 3 through 20 in order to avoid assumptions of benefit that are not
proven by longer term follow-up. Therefore, identical probabilities of risk for stroke,
reintervention, and death were applied for this time period, based on disease-specific
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probabilities from published literature. Probability of death after 2 years was estimated from
an observational trial providing survival curves up to 20 years post-CABG. Importandy, it
was also assumed the neurocognitive dysfunction unrelated to stroke would be identical for
the two groups after 2 years.
4.2.5 Utilities
Quality-adjusted life years, which combine the preference for a specified health state and the
time spent in that state into a single quantitative measure, were used in this analysis to
provide a measure of effectiveness. Utility values for each health state considered in the
model were derived from the literature. Appendix N outlines utilities assigned to health
states in the decision model and their sources. Utiilties from two published studies of
OPCAB versus CCAB were used in the decision tree. Puskas et atand Nathoe et atprovided
EuroQoL scores at I year post-surgery in patients randomized to OPCAB or CCAB, and
also calculated QALYs at I year (Puskas 2004; Nathoe 2003). Published utilities for acute
and chronic effects of stroke were taken from a published study that matched patient
reported preferences for stroke outcomes to the prevalence of stroke outcomes (measured as
Rankin Scores) in a patient population treated for acute ischemic stroke in the hospital
setting (Sinclair 2001).
Since no direct measures of utility for neurocognitive dysfunction (NCD) in post-OPCAB or
post-CCAB patients have been published, utilities for NCD were derived from an extensive
study of change in cognitive function and change in quality of life after bypass surgery
(Phillips-Bute 2006). In this study a well-validated battery of five neurocognitive tests and
nine QoL instruments [including the Duke Activity Status Index (DASI), Duke Older
Americans Resources and Services Procedures Instrumental Activities of Daily Living
(OARS-IADL), Medical Outcomes Study 36-item Short Form Health Survey (5F-36), The
Cognitive Difficulties Scale, Center for Epidemiological Studies Depression Scale (CES-D),
Spielberger State Anxiety Inventory (STAI), Perceived Social Support Scale, Social Activity
Scale, and Symptom Limitations Scale] were administered before surgery, and at 6 weeks and
1 year post surgery. A composite cognitive index was calculated as the mean of four domain
scores to yield a single continuous summary measure. The change in composite cognitive
index was calculated as a continuous score representing the difference benveen baseline and
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I year scores. Since no validated methodology for combifflng domains of QoL vas available
for dais study, the investigators explored each QoL instrument and the change in composite
cognitive index separately through multivariate linear regression. The study found that post
CABG cognitive decine was apparent at 6 weeks. This early decine was associated with
diminished QoL at 1 year, and was assumed to be equivalent to a utility of 0.02 at 6 weeks
and 0.75 after I year. Since there was no evidence to suggest the utility associated with
OPCAB differs from that of CCAB, it was assumed that the utility would be similar for both
groups for this analysis. The ranges used for sensitivity analyses were large, given the
uncertainty regarding the assumptions used for utilities.
It was assumed that most post-operative complications would not materially impact QALYs
since their duration of impact would be short in the context of a lifetime; therefore,
immediate post-operative complications were not assigned ïndividual utilities. Rather, an
overail post-procedure utffity was assigned to reflect average utility post-procedure in ail
patients combined. The utility for each brandi was assigned and multiplied by the time
weight represented by the number of cycles during which the utility vas assigned. Values for
each brandi were summed over the entire time horizon to give the overail expected utility.
4.2.6 External Validity
A common criticism of randomized trials is that patients enrolled are not generally
representative of patients in cinical practice. for example, randomized trials of coronary
intervention have been found to enroil younger patients with a better cardiovascular risk
profile when compared with patients undergoing coronary intervention in every day cinical
practice. (Hordijk-Trion 2006). Indeed, comparison of the baseline characteris tics of patients
included in the meta-analysis reveals a general]y younger population than ma1’ be typical of
some cardiac surgical practices (Cheng 2005). Given this disparity between patients in cinical
practice and randomized trials, the resuits of our decision model were compared to the
results obtained after substituting the probability of cinical events reported randomized
trials for those reported in obsenrational (naturalistic) studies of OPCAB and CCAB from
other institutions (Lamy 2006, Wijeysundera 2005). In addition, costs were ascertained from
another Canadian cost analysis (Lamy 2006) to determine coherence with other experiences.
2$
The resuits of our base case analysis were compared with the fesuits obtained when costs
from external institutions were substituted for ail local costs included in the model.
4.2.7Analysis
For the baseline analysis, the present value for the lifetime cost per QALY gained following
OPCAB and CCAB was calculated for a cohort of average-risk 63 year old patients
undergoing multi-ves sel revascularization. According to current recommendations, ah future
costs and health benefits were discounted at a constant rate of 3% per annum and allowed to
vary from 0% to 5% in sensitivity analyses (CADTH 2006, Garber 1996).
The incremental cost effectiveness ratio ÇICER) was calculated for the base case analysis, and
for each sensitivity analysis, according to the following formula:
ICER Mean cost
— Mean cost CCAB =
Mean QALY OPCAB — Mean QALY CCt\3 A E
In addition, the incremental net monetary benefit (INMB) assuming a societal threshold of
willingness to pay (WTP) of 50,000$ was calculated as follows:
INMB = WTP*AEAC
4.2.8 Sensitivity Analyses
A number of sensitivity analyses were conducted to assess the impact ofvarying cost and
effectiveness assumptions, individually and in aggregate, across plausible ranges of values
(O’Brien 1994). One-way sensitivity analyses were conducted across the ranges assigned to
each variable (Appendices J, M, N) and Tornado diagrams were created to visualize which
variables have the greatest influence on cost-effectiveness estimates. In addition,
probabilistic sensitivity analysis was performed using Monte Carlo simulation (10,000
samples) to ailow for variation in ail parameters simultaneously across plausible values. Cost
variables were assigned gamma distributions, and cinical probabilities or utilities were
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assigned beta distributions. The parameters of these distributions were estimated using mean
and standard deviations for each variable. Scatterpiot and isocontours graphs were
generated to assess the range of ICER estimates and their 95% confidence intenrals plotted
on the cost-effectiveness plane. In addition, the cost-effectiveness analysis curve (CEAC)
was generated to assess probability of cost-effectiveness at varying thresholds of societal
“XTP. Expected value of perfect information was calculated to assess whether further
research should be encouraged before policy decisions are made regarding OPCAB versus
CCAB.
4.3 Decision Analysis for High risk groups
Since the base case analyzed average-risk patients, further scenario analyses were performed
to address the risk of specified high risk groups. Probabilities for the following risk groups
were derived from meta-analysis of 45 randomized and non-randomized comparative trials
of OPCAB versus CCAB involving 26 349 patients (Cheng 2006): advanced age (>70 years),
or preexisting renal failure, clironic obstructive pulmonarv disease, atheromatous aorta, left
ventricular dysfunction, diabetes, redo or urgent revascularization, or Euroscore 5 (refer to
Appendix O) Utilities were assumed to be similar for average-risk and high-risk groups.
Using the same tree architecture as for the average-risk cohort, a separate analysis was
conducted for each risk group after imputing specific probabilities for the group.
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4.4 Decision Tree for OPCAB versus PCI in Low-Risk
Patients with Single-Vesse! Disease
4.4.1 Analytic Mode!
To assess the cost-effectiveness of OPCAB in low-risk patients, a revised decision tree was
created. The decision node posed the question: What is the best interventional strategy for
managing low-risk patients who present with single vessel and are eigible for
revascularization with either percutaneous coronary intervention (PCI) or off-pump CABG
(OPCAB)? A compressed representation of the decision tree is found in Figure 3, and the
full decision tree is displayed in Appendix P.
FÏgufe 3: Compressed Decision Tree of 5-State Markov Model for OPCAB versus PCI
The Bye health states in the Markov model were as follows: initial OPCAB, angina
recurrence, stroke, post-procedure (uncomplicated by angina recurrence, stroke, or death),
and death. Appendix Q outlines the tree with only one Markov state expanded for better
visualization.
Initial OPCAB (-f-J
(1
(1
(1OPCAB vs
Clone 1: PCI Procedure
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4.4.2 Model Inputs
The target group for the baseline analysis was a hypothetical cohort of average-risk patients
(32% female, 22% diabetic) for revascularization who were 59 years of age and who were
eligible for surgical revascularization of multi-vessel CAD. The demographics of the
hypothetical cohort group matched those of the summary patient characteristics in the meta
analysis of 6 randomized trials (949 patients) from which cinical probabilities were derived
for this analysis (Cheng 2006). Since the meta-analysis provided data up to 2 years, event
rates after that time were assumed not to differ between groups, and were derived from
observational trials. Appendix R oudines the probabilities and utilities used in this analysis.
Utilities were derived from external published sources.
A cohort of LHSC patients undergoing on-pump CCAB between 2003 and 2004 was used
to estimate hospital costs for PCI, and included direct and indirect costs as described in the
OPCAB versus CCAB methodology. Physician costs (surgeons, anesthesiologists, daily visits
in hospital and procedural fees), which were not included in the LHSC database, were
derived from the OHIP Schedule of fees. It was assumed that a perfusionist would be
required for OPCAB since perfusionists are routinely employed to ‘stand by’ in the case of
the need for emergency conversion to on-pump surgery. The cost of stents was also
included. An average of 0.7 BMS stents and 0.9 DES (either Cypher or Taxus) was used for
each coronary intervention, based on our institutional data. The cost of drug-eluting stents
was CDN 2700$ per Cypher stent, and 1475$ per Taxus stent, and the average ratio of
Cypher to Taxus stents was 1:13. Therefore, the mean total stent costs per patient was CAN
1837$. Costs used in the OPCAB versus PCI tree are oudined in Appendix S. It vas
assumed that most of the complications would cost the same as for the previous model.
However, for reintervention, it was assumed that 33% of patients would undergo OPCAB,
33% CCAB, and 33% PCI. As a result, the cost of reintervention is a reflection the mean
cost of ail three of these.
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4.4.3 Analysis and Sensitivity Analyses
Using the revised tree, the same methodology for cost-effectiveness was used for this
analysis as for the analysis of OPCAB versus CCAB. Similar sensitivity and validation
methodology was applied. Probabilistic sensitivity analysis was performed and scatterpiots
were generated.
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CHAPTER 5
RESULTS
This chapterpresents the resitÏts of the base case ana/ysis and secondarji anaiysesfor OPAB versus CC/IB
in average-ns/e and /ugb-7sk patients. It atso presents the resuts of the base case and seconday anaj’sesfor
OPCAB versus PCI in loiv-risk patients. The ciJapter closes with sensitiviy ana/yses scenario ana/yses, and
assessment of expecteil value ofpefect information..
5.1 OPCAB versus CCAB in average-risk patients with mufti-vesse!
disease
Table I oudines the summary statistics for the expected value of OPCAB and CCAB in
average-risk patients with multi-vessel CAD generated from the probabilistic sensitivity
analysis.
Table I: OPCAB vs CCAB Summary Statistics
Stratcgy Cost, $ 95%C1 Effect, QALYs 95% CI
OPCAB 68 339 43 002 to 107 219 8.28 4.54 to 10.21
CCAB 77593 46586toJ27235 8.16 4.57to10.12
5.1.1 Estimates ofCosts
The average lifetime cost for OPCAB was 68 339$ (95%CI, 43 002 to 107 219$), and for
CCAB vas 77 593$ (95%CI, 46 586 to 127 235$). The distribution ofcosts for OPCAB and
CCAB are shown in Figure 4. As expected, the distributions are right skewed, given their
assigned gamma distributions.
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Figure 4: Distribution of Costs for OPCAB and CCAB
5.1.2 Estimates ofEffectiveness for OPCAB versus CCAB
The average lifetime QALY gained for OPCAB \vas 8.28 (95°/0CI, 4.54 to 10.21), and for
CCAB was 8.16 QALYs (95%CI, 4.57 to 10.12 QALYs). The distribution of QALYs for
OPCAB and CCAB are shown in Figure 5.
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Figure 5: Distribution of Effectiveness for OPCAB and CCAB
5.1.3 Estimates ofMean Cost per Effect (C/E)
The mean cost per QALY was 8708$ (95%CI, 4620 to 16 813$) for OPCAB and 9973
(95%CI 5275 to 19 134$) for CCAB. Figure 6 outlines the distributions in cost per QALY
for OPCAB and CCAB.
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Figure 6: Distributions of C/E for OPCAE and CCAB
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5.1.4 Cost-Effectiveness
Table II outiines the incremental costs and incremental effectiveness for OPCAB versus
CCAB in average-risk patients with multi-vessel CAD. The resuits show that OPCAB vas
less cosdy (savings of 9234$) and more effective (0.12 more QALYs gained) than CCAB.
Therefore, CCAB ïs dominated by OPCAB in terms of cost-effectiveness. The ICER was
estimated as (-) 76 950$/QALY, suggesting cost-savings to the health care system (improved
outcomes, reduced costs) when OPCAB is performed rather than CCAB in this patient
population. The ICER estimates remained similar regardless of perspective used during the
analysis.
Table II: Incremental Cost-Effectiveness of OPCAB versus CCAB
Health Care System (Base Case)
OPCAB 68486 8.187 8,365 $/QÀLYs (-) 76 950
CCAB 77720 9234 8.068 -0.12 9,633 $/QALYs (Dominated)
Society
OPCAB 95431 8.187 9,032 $/QALYs (-) 82 542
CCAB 105336 9905 8.06$ -0.12 10,311 $/QALYs7 (Dominated)
Institution
OPCAB 60976 8.187 7,44$ $/QALYs (-) 76 758
CCAB 70188 9211 8.068 -0.12 8,700 $/QALYs (Dominated)
Figure 7 displays the range of incremental cost effectiveness ratios for OPCAB versus
CCAB and highlights their domain concentrations as isocontours on the cost-effectiveness
plane. The dotted lime represents the societal wïflingness to pay, and estimates faffing below
this lime represent cost-effective options. Further detail is available in Appendix T, which
displays the range of point estimates for the ICERs generated during probabilistic sensitivity
analvsis (10 000 samples) in a scatterpiot.
Strategy Cost Cost Effcct, Effect C/E C/ E
$ $ QALYs $/QALY $/QALY
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Figure 7: Isocontour Plot of OPCAB versus CCAB
\Tisual inspection of the isocontoufs on the cost-effectiveness plane reveals that the highest
concentration of ICER estimates were within the cost-savings quadrant (Quadrant IV), and
the majority of estimates remaïned below the societal willingness to pay threshold of 50
000$/QALY, even when ail uncertainty vas included in the parameters.
Table III oudines the probability of ICER estimates within each quadrant of the cost
effectiveness plane, and the cumulative probability that the ICER remains below the 50
000$/QALY threshold. There was an 80% probabiiity that OPCAB is cost effective, as
defined by a wiflingness to pay of 50000$/QALY, and a 20% probability that it would flot be
cost-effective based on this definition. There vas a 7.7% chance that OPCAB would be
inferior (less effective and more cosdy) than CCAB.
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5.1.5 Cost-effectiveness Acceptabffity Curve
Plotting proportion of estimates that were cost-effective versus WTP reveals that the
probability that OPCAB wffl be considered cost-effective remains close to 80% regardless of
the definition of cost-effectiveness threshold (Figure 8).
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Figure 8: Cost Effectivencss Acceptability Curve for OPCAB
versus CCAB in Average-Risk Patients
Table III: ICER Scatterpiot Summarr
Component I Iv IE>0
ort for OPCAB versus CCAB
IC<0
Component 2 I IE>0
Component 3 III IE<0
Supenor
Component Quad E C ICER # Points Percent Description
6360 53.5
Overail Probabffity of Cost-Effectiveness for OPCAB versus CCAB
Cost effective
(Dominant)
IC>0 <50000 720 10.8 Cost-Effective
IC<0 >50000 1880 15.2 Cost-effective
79.5
Component 4 1 IE>0 IC>0 >50000 110 8.3 Not cost effective
Component 5 III IE<0 IC<0 <50000 680 4.5 Not cost-effective
Component 6 II IE<0 IC>0 Inferior 250 7.7 Not cost-effective
(Inferior)
Overail Probability of Non Cost-Effectiveness for OPCAB versus CCAB 20.5
Component I is where OPCAB is dominant (‘superior’).
Component 2 is where OPCAB is more costly, but lies below the WTP.
Component 3 is where OPCAB is less costly, but lies below the WTP.
Component 4 is where OPCAB is more costly, and lies above the WTP.
Component 5 is where OPCAB is less costly, and lies above the WTP.
Component 6 is where OPCAB is dominated (inferior).
OPCAB
• CCAB
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5.1.6 Net Monetary Benefits
The net monetary benefit (NMB) was estimated to be 340 864$ (95%CI 155 834 to 453
425$) for QPCAB and 325 680$ (95%CI 322 330 to 441 304$) for CCAB. The incremental
net monetary benefit INMB) vas estimated to be 3234$, assuming a WTP of
50000$/QALY.
5.1.7 Expected Value of Perfect Information (EVPI)
Therefore, the expected value of perfection information vas calculated to be $1997,
assuming a societal wiffingness to pay of 50 000$ and a baseline net monetary beneHt of
OPCAB of 354 705$ (Figure 9).
Monte Carlo Simulation
EVPI (NMB with WTP = 50000.)
$350K-
EVPI
$300K- D Baseline (OPCAB)
$250K-
$200K-
$150K-
$100K-
$50K-
figure 9: Expected Value of Perfect Information for OPCAB versus CCAB
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5.1.8 Sensitivity Analysis
Si. 8.1 Tomado Diagrams
Tornado diagrams revealed that the variables with most influence on cost-effectiveness was
the utility for post-procedure health state, utility for stroke health state, probability of stroke
at 2 years, and cost of post-stroke management (Figure 10). Probabilistic sensitivity analysis
accounted for the uncertainty across these variables in generating our cost-effecdveness
estimate s.
Tornado Diagram at
OPCAB vs CCAB
_______________________
PostProcedure QALY
_____
Li Stroke QALY
t••••••••i ProbofStroke2yCCAB
Li Cost 0f PostStroke Mgt
D CostofOPCAB:
• Neurocog QALY
L] Prob of Stroke 2 y OPCAB
PreProcedure QALY
D Prob of Death 2 y OPCAB
ProbofNCD30dCCAB
250K 290K 330K 370K 410K
Prob NCD 2y OPCAB
Net Monetary Benefit (wtp=50k)D Prob NCD 2y CCAB
Figure 10: Tornado Diagram for OPCAB versus CCAB
5.1.8.2 One-way sensitivity analyses
One-way sensitivity analyses were performed to evaluate cadi of these influendal variables to
assess their impact on the esdmated ICER. Ail one-way sensidvity analyses demonstrated
that OPCAB remained the dominant option regardless of variation across the plausible
range of values for each variable. One-way sensitivity analysis xvas also conducted to assess
the impact of increasing the effective duration of benefit for OPCAB beyond 2 years. As
shown in Table IV, the esdmated ICER for OPCAB improves with increasing duration of
benefit of OPCAB if assumed to continue beyond 2 years.
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Table IV: One Way Sensitivity Analysis of Duration of OPCAB Benefit
• I1TTII -I ê —(i W
2 OPCAB 68486 8.187 (-) 77 597
CCAB 77720 8.068 (dominant)
5 OPCAB 64314 8.461 (-) 39 531
CCAB 78071 8.113 (dominant)
10 OPCAB 62536 8.899 (-) 32 650
CCAB $0069 8.362 (dominant)
15 OPCAB 62493 9.247 (-) 30 425
CCAB 82300 8.596 (dominant)
20 OPCAB 62772 9.383 (-) 29 989
CCAB 83375 8.696 (dominant)
5.1.9 Scenario Analysis
Scenario analyses were performed to estimate cost-effectiveness for different perspectives,
including the societal perspective and the institutional perspective. As shown in Table V,
ICER estimates remained similar regardless of perspective used during the analysis.
Table V: ICER Estimates Across Different Per ctivesI
Strategy Cost z C Effect iX E C/E iX Cf iX E
$/QALY $/QALY
Health Care System
OPCAB 68486 8.187 8,365 (-) 76 950
CCAB 77720 9234 8.068 -0.12 9,633 (Dominated)
Society
OPCAB 91953 8.187 9,032 (-) 76 942
CCAB 83186 9233 8.068 -0.12 10,311 (Dominated)
Institution
OPCAB 60976 8.187 7,448 (-) 76 758
CCAB 70188 9211 8.068 -0.12 8,700 (Dominated)
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5.2 OPCAB versus CCAB in High-Risk Patients with Mufti
Vessel Disease
Scenario analyses for individual Hgh-risk groups undergoing surgical revascularization for
multi-vessel disease demonstrated variation in estimates of magnitude of cost-savings and
QALYs gained; however, ICER estimates remained similar to die base case analysis (Table
vI.
Table VI: ICERS for OPCAB versus CCAE in W - Risk Patient Sul s
Strategy Cost A C Effect A E A C, A E (ICER)
EuroScore 5+
OPCAB 64202 8.172 (-) 15 499
CCAB 72556 8354 7.634 -0.539 Dominated)
COPD
OPCAB 66279 8.312 (-) 25 837 (Dominated)
CCAB 77725 11446 7.869 -0.443
Diabetes
OPCAB 67093 8.006 (-) 20 798 (Dominated)
CCAB 71523 4430 7.794 -0.2 13
Elderly
OPCAB 99037 7.06 (-) 35 645
CCAB 113616 14579 6.651 -0.409 @ominated)
Renal failure
OPCAB 66451 8.172 (-) 15 319
CCAB 73513 7062 7.711 -0.461 tDominated)
Ieft Ventncular Dys fonction
OPCAB 88633 6.99 t-) 5419
CCAB 91234 2601 6.51 -0.48 (Dominated)
Atheromatous Aorta
OPCAB 70201 8.001 (-) 37 098
CCAB 78177 7976 7.786 -0.215 tDominated)
Left Main CAD
OPCAB 63243 7.942 t-) 7108
CCAB 69925 6682 7.002 -0.94 @ominated)
Redo or Urgent CABG
OPCAB 89625 7.99 t-) 4785
CCAB 91204 1579 7.63 -0.33 tDominated)
Multiple High Risk Factors
OPCAB 68456 8.012 (-) 29 210
CCAB 77510 9055 7.7 -0.311 tDominated)
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5.3 Model validation
Validation of our model, by imputing probability estimates and costs from observational
studies ffom other centres, resulted in ICER estimates that concurred with our base case
analysis (Table VII).
Table VII: ICERS with Real World Probabifities
Lamy 06
OPCAB 66060 7.798 8471 $/QALYs (-) 371 967
CCAB 77219 11159 7.768 -0.03 9940 $/QALYs (Dominated)
Wijeysundera 2005
OPCAB 70947 8.200 8652 $/QALYs (-) 40 741
CCAB 79299 8352 7.995 -0.205 9918$/QALYs (Dominated)
5.4 OPCAB versus PCI in Low-Risk Patients with Single
Vessel Disease
Table VIII outiines the summary statistics for the expected value of OPCAB and PCI in
low-risk patients with single-vessel CAD generated from the probabilistic sensitivÏty analysis.
Table VIII: OPCAE versus PCI Summary Statistics
Stratcgy Cost, $ 95%CI Effcct, QALYs 95% CI
OPCAB I 55 266 I 37 319 to 78 089 I 8.538 I 4.18 to 10.686
PCI 67187 44640 to 95 775 8.808 4.358 to 11.014
5.4.1 Estimates of Costs
The average lifetime cost for OPCAB was 55 266$ (95%CI, 37 319 to 78 089$), and for PCI
was 67 187$ (95%CI, 44640 to 95 775$). The distribution ofcosts for OPCAB and PCI are
shown in figure 11.
Strategy Cost C Effect E dE C/Z E (ICER)
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Figure 11: Distribution of Costs for OPCAE and PCI
5.4.2 Estimates ofEffectiveness for OPCAB versus PCI
The average lifetime QALY gained for OPCAB vas $.54 (95%CI, 4.1$ to 10.69 QALYs)
and for PCI vas 8.81 QALYs (95%CI, 4.36 to 10.72 QALYs). The distribution ofQALYs
for OPCAB and PCI are shown in the Figure 12.
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Figure 12: Distribution of Effects for OPCAB and PCI
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5.4.3 Estimates ofMean Cost per Effect (C/E)
The mean cost per QALY was 6917 (95%CI, 3889 to 13 823) for OPCAB and 8097 (95%CI
458$ to 16 011) for PCI. Figure 13 outlines the distributions in cost per QALY for OPCAB
and PCI.
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Figure 13: Distribution of C/E for OPCAB and PCI
5.4.4 Cost-Effectiveness
Table IX outlines the incremental costs and incremental effectiveness for OPCAB versus
PCI in iow risk patients with single-vessel disease. The resuits show that OPCAB was less
costiy (by 11 921$) and less effective (0.27 fewer QALYs gained) than PCI. The ICER vas
estimated as 44 151$/QALY, suggesting a lifetime cost to the health care system ofover 44
000$ per QALY gained when PCI is performed rather than OPCAB in low risk patients with
single-vessel disease. However, examination of the uncertainty around this ICER estimate
reveals that neither strategy is clearly dominant, as the probability of cost-effectiveness varies
considerably across assumptions.
Table IX: Incremental Cost-Effectiveness of OPCAB versus PCI
Strategy Cost zC Effcct zC / zE
$ $ QALY QALY $/QALY
OPCAE 55 266 8.538
PCI 67187 11921 8.808 0.27 44151
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figure 14 displays the range ofincremental cost effectiveness ratios for OPCAB versus PCI
and highlights their domain concentrations as isocontours on the cost-effectiveness plane. A
more detailed scatterpiot in Appendix U displays the range of point estimates for OPCAB
versus PCI ICERS generated during probabilistic sensitivity analysis (10 000 samples). Visual
inspection of the isocontours on the cost-effectiveness plane reveals that the ICER estimates
generated by probabilistic sensitivity analysis span two quadrants, with similar proportions
of estimates remaining above and below the societal willingness to pay threshold of 50
000$/QALY (indicated by the dashed lime).
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Figure 14: Isocontour Plot for OPCAB versus PCI
Table X outlines the probability of ICERs within each quadrant, and the cumulative
probability that the ICER remains below the 50 000$/QALY threshold.
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Table X: ICER Scatterpiot Summary Report for OPCAB versus PCI
IE>0 IC>0 <50000 0 0 Cost effective
IE<0 IC<0 >50000 4490 44,9 Cost Effective
Overail Probabilitv of Cost-Effectiveness for OPCAB versus PCI 44.9
Component 4 I IE>0 IC>0 >50000 0 0 Not Cost Effective
Component 5 III IE<0 IC<0 <50000 3580 35.8 Not Cost Effective
Component 6 II IE<0 IC>0 Inferior 1930 19.3 Not cost effective
(inferior)
Overail Probabffity of Non Cost-Effectiveness for OPCAB versus PCI 55.1
Component I is where OPCAB is dominant (‘superior’).
Component 2 is where OCPAB is more costly, but lies beiow the WTP.
Component 3 is where OPCAB is less cosdy, but lies below the WTP.
Component 4 is where OCPAB is more cosdy, and lies above the WTP.
Component 5 is where OPCAB is less cosdy, and lies above the WTP.
Component 6 is where OPCAB is dominated (‘inferior’),
5.4.5 Cost-Effectiveness Acceptabffity Curve
Plotting cost effectiveness by willingness to pay, the cost-effectiveness acceptability curve
reveals the designation of which strategy is deemed to be cost-effective depends heavily on
what is the definition of the cost-effectiveness threshold (Figure 15). At the typical societal
threshold of 50 000$/QALY, the probability that either strategy should be considered cost
effective approaches equivalence (ie, 45% probability that OPCAB is cost-effective versus
55% probability that PCI is cost-effecdve).
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Figure 15: Cost Effectiveness Acceptabffity Curve for OPCAB versus PCI
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5.4.6 Net Monetary Benefit
The estimated net monetary benefit (NMB) for OPCAB was esdmated to be 371 643$
(95%CI 155 278 to 486 352$) and for PCI it was 373213$ (95%CI 146 965 to 490 405$).
The incremental net monetary benefit was estimated to be 1579$ for choosing PCI instead
of OPCAB in patients with single vessel disease.
5.4.7 Expected Value of Perfect Information (EVPI)
The expected value of perfect information was calculated to be $4850.059, assuming a
societal wiffingness to pay of 50 000$ and a baseline PCI net monetaty benefit of 373213$.
This suggests that the maximal incremental net monetary benefit to be gained if there was
perfect information, would be less than 5000$ (Figure 16).
Monte Carlo Simulation
EVPI (NMB wïth WTP = 50000.)
EVPI
E Baseline (PCI)
A flflV
•-rU.jI ‘-
$350K-
$300K-
$250K-
$200K-
$150K-
$100K-
$50K-
n’<.
Figure 16: Expected Value ofPerfect Information for OPCAB versus PCI
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5.4.8 Sensitivity Analysis
5.4.8.1 Tomado Diagrams
Tornado diagrams (Figure 17) revealed that die variables wïth most influence on cost
effectiveness estimates were the utility ofpost-procedure state, probability of stroke after
PCI, cost of reintenrention, cost of post-procedure follow-up, utility of pre-procedure state,
and probability of reintervention after PCI. Probabilistic sensitivity analysis incorporated the
full range of uncertainty across these variables in generating our cost-effectiveness estimates.
Other variables did not materially affect the results.
Tornado Diagram at
OPCAB vs PCI
I 1H E
I E
E
11111111 II•I 111111111
270K 320K 370K 420K 470F
Net Monetary Benefit (wtp=50k)E
PostProcedure QALY
Prob of Stroke 2 y PCI
Cost of Reintervention after 30d
Cost of PostProcedure F/U > lyr
PreProcedure QALY
Prob Reintervention 2 yr PCI
Cost of PCI
Cost of OPCAB4
Acute costs of stroke
Prob of Reintervention OPCAB
Cost of Angina beyond 30d
Cost of Outpatient Followup Yr 1
Prob of Stroke 2 y OPCAB
Acute Angina QALY Reduction
Figure 17: Tornado Diagram for OPCAB versus PCI
5.4.8.2 One- Way SensitivftyAnalysis ofPost-Procedure Utility
One way sensïtivity analysis of post-procedure utility revealed that the incremental cost
effectiveness of PCI relative to OPCAB continued to improve as die utility of the post
procedure state improves, and PCI remains cost-effective throughout the plausible ranges of
post-procedure quality oflife (Table XI).
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PCI 67285 11814 6.921 0.252 9,722 $/QALYs 46,810
0.7 OPCAB 55471 7.645 7,256 S/QALYs
PCI 67285 11814 7.909 0.264 8,507 $/QALYs 44,760
0.8 OPCAB 55471 8.622 6,434 $/QALYs
PCI 67285 J 1814 8.897 0.275 7,563 $/QALYs 42,881
0.9 OPCAB 55471 9.598 5,779 $/QALYs
PCI 67285 11814 9.885 0.287 6,807 $/QALYs 41,154
I OPCAB 55471 10.575 5,246 $/QALYs
PCI 67285 11814 10.873 0.299 6,188 $/QALYs 39,561
0.317 5,912 29 978
Probability Strategy Cost C Effect L E C/E C/ E
Stroke, 2v $ $ QALY QALY $/QALY (ICER)
PCI
OPCAB 54853 8.632 6,354
PCI 66540 11687 8.91 0.278 7,468 42 067
0.0004
0.010375
0.02035 OPCAB 64283 8.469 7,590
PCI 77881 13598 8.712 0.243 8,939 55 964
0.030325 OPCAB 72845 8.32 8,755
PCI 88125 15280 8.532 0.212 10,329 72 023
0.0403 OPCAB 80631 8.184 9,852
PCI 97392 16762 8.369 0.185 11,638 90697
Table XI: One “y sensitivit’ Analysis of Post-Procedure Utility for PCI
0.6 OPCAB 55471 6.668 8,31 8 $/QALYs
5.4.8.3 One-Way Sensitivity Analysis of Stroke at 1
— 2 years
In one-way sensitlvity analysis of the probability of stroke at 1-2 years after PCI, the cost
effecdveness of PCI changes as the ]ikelihood of stroke increases (Table XII). When the
probability of stroke reaches l.8%, the ICER for PCI exceeds the WTP threshold of
50000$/QALY.
Table XII: One-Way Sensitivity Analysis of Probabffity of Stroke at 2 years for PCI
OPCAB
PCI
44454
53964
8,811
9509
5,045
9.128
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The graph depicts the incremental cost effectiveness of PCI as stroke varies. The vertical
dotted lime represents the baseline risk of stroke in the decision tree from the meta-analysis
(0.004), and the horizontal dotted lime represents the \VTP threshold of 50000$/QALY.
Sensitivity Analysis on Probability of
Stroke J —2years for PCI
100K$/QALYs-
- OPCAB
90K $/QALYs-
• PCI80K $/QALYs
70K $/QALYs
o 60K $/QALYs
50K $/QALYs-
CQ) 40K $/QALYs
30K $/QALYs
20K $/QALYs
— 10K $/QALYs
0K $/QALYs- - r
0.00040 0.02035 0.04030
Prob of Stroke 2y CCAB
Figure 18: One-Way Sensitivity Analysis for Stroke at 2 Years in PCI Group
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5.5 Scenario Analysis
Scenario analyses were performed to estimate cost-effectiveness for different perspectives,
including the societal perspective and the institutional perspective. As shown in Table XIIi,
ICER estimates remained similar regardless of perspective used during the analvsis.
Table XIII: Incremental Costs and Effectiveness across Va “- P ectives
Heahh Care System
OPCAB 55 266 8.538 6473
PCI 67 187 11921 8,8t 0.270 7628 44 152
Societal
OPCAB 82 840 8.622 7289
PCI 90 261 7421 8.897 0.275 7897 26 936
Institutional
OPCÀB 52 875 8.622 6133
PCI 64450 11575 8.897 0.275 7244 42016
5.6 External Validity
Comparing the results of our base case analysis which used probabilities from randomized
trials and local costs to those obtained after imputing probability estimates and costs from a
retrospective trial of OPCAB versus PTCA (Shirai 2004) and from a retrospective trial
comparing OPCAB versus DES, revealed that the ICER for PCI became more attractive
when ‘real world’ estimates were entered (Table XIV).
Table XIV: ICERS with Real World Probabffities for OPCAB versus PCI
Shirai 2004 (OPCAB versus PTCA)
OPCAB 60591 8.60 7045
PCI 67099 6508 8.90 0.30 7539 21 693
Herz 2005 (OPCAB versus DES)
OPCAB 50 119 8.673 7,289
PCI 55 921 5802 8.969 0.296 7,897 19 601
Strategy Cost C Effcct E C/E 1 C, E
$ $ QALY QALY $/QALY $/QALY
Strategy Cost C Effect E dE Cf E
$ $ QALY QALY $/QALY $/QALY
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CHAPTER 6
DISCUSSION & CONCLUSIONS
This chapter e.ptores the resutts ofthe cost-eectiveness ana/ysis and their impticationsforpractice. Broader
issues of economics, ffica’, fflcien and eql/ijI are discussed. The cl]apter closes bj’ rna/eing recommendations
based on the conclusion of this economic antiysis.
6.1 Overvïew of Resuits
Meta-analysis of 37 randomized trials comparing OPCAB versus CCAB in average-risk
patients has demonstrated that OPCAB may be superior for short term perioperative
outcornes, but the relative efficacy over time is uncertain (Cheng 2005). Similarly, meta
analysis of 45 randomized and non-randomized direct comparisons of OPCAB versus
CCAB in high risk subgroups bas demonstrated superioritv for OPCAB for perioperative
risks, but the efficacy at later time points remains understudied in higher risk patients(Puskas
2005). for OPCAB versus PCI in low-risk patients, meta-analysis of 6 randomized trials bas
demonstrated that OPCAB is superior for selected short term and longterrn outcomes such
as angina recurrence and need for surgical or percutaneous coronarv intervention (Cheng
2006). The upfront in-hospital costs of OPCAB are lower than CCAB, but higher than PCI.
In this analysis, a decision model was used to assess the cost-effectiveness of OPCAB
relative to the CCAB in average-risk and high-risk patients with multivessel CAD, and to
assess the cost-effectiveness of OPCAB relative to PCI in low-risk patients with single vessel
CAD. Since the relevant comparator to OPCAB changes, depending on the number of
target vessels requiring revascularization, this economic analysis required two decision
analysis models \vith slightly different architecture, to accommodate analysis of the two
different cohorts (multi-vessel and single vessel disease).
The primary cifflcal endpoint in this analysis was cost per QALX over a Ufetime, from die
Canadian liealth care system perspective. In Canada, most healtli care resources are
administered at the provincial level, and as a result the health care perspective analyzed in
this analysis represented the provincial Ivllnistry of Health (MOI-1). Secondary analyses were
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conducted to assess the cost-effectiveness from other perspectives, including the institution
and the broader societal perspective. Additional analyses were undertaken to explore the
impact of substituting ‘real world’ data into the model to replace the data derived from
randomized trials.
This latter set of analyses was conducted to address the concern that patients recruited into
randomized trials may not be representative of patients encountered in the real world setting.
However, randomized trials were used as the basis for the primai-y analysis since non
randomized trials have been shown to be influenced by selection bias (Cheng 2005, Puskas
2005, Wijeysundera 2005) which may inherendy favour OPCAB over CCAB in patients with
multi-vessel disease when lower risk patients are selected preferentially for OPCAB, and
disadvantage OPCAB patients when higher risk patients are preferentially selected compared
with PCI in the nonrandomized setting.
6.1.1 Incremental Cost-Effectiveness of OPCAB Across Patient Risk
Groups
In the base case analysis for patients with multi-vessel disease, while both OCPAB and
CCAB resulted in QALYs gained, OPCAB vas less cosdy and more beneficial in terms of
improving QALYs gained. The ICER was dominant, suggesting that, over a lifetime, nearly
77 000$ per QALY may be saved or released to the health care system for alternative uses
when OPCAB is performed rather than CCAB in average-risk patients with multi-vessel
disease. The ICER remained similar, regardless of whether resources relevant to the
institution or to the broader society were considered. In secondai-y analyses of high risk
subgroups, OPCAB remained dominant over CCAB, and in some cases the estimated
lifetime cost-savings vas greater than in average-risk patients. Substituting real world
estimates for randomized trial data resulted in ICERS that also suggested dominance of
OPCAB over CCAB. Therefore, according to this analysis, OPCAB should be considered a
wise use of health care system and societal resources since it is a cost-saving alternative to
CCAB in average-risk and high-risk patients with multi-vessel disease. Even when alI
uncertainty across model parameters was incorporated into the analysis, there remained an
80% probabilitv that OPCAB would be considered dominant over CCAB.
55
In the base case analysis for patients with single-vessel disease, whule both OCPAB and PCI
resulted in QALYs gained, PCI was more beneficial but more cosdy than OPCAB. The
ICER was estimated to be 44 152$/QALY gained, suggesting that, over a lifetime, over 44
000 additional dollars would be required per QALY gained when choosing to PCI rather
than OPCAB. The conclusion remained similar from the institutional perspective, and vas
even more desirable from the societal perspective. In secondary analyses of real world
probabilities, the ICER became even more favourable for PCI compared with the base case
analysis. Therefore, according to this analysis, PCI should be considered a wise use ofhealth
care system and societal resources since it appears most likely to be a cost-effective
alternative to OCPAB in patients with single vessel disease. Nevertheless, it is important to
note that when ail uncertainty across model parameters was incorporated into the analysis,
there was a 45% probability that OPCAB might be considered cost-effecdve, as defined by
a WTP of 50 000$/QALY. Therefore, there remains significant uncertainty whether PCI can
be considered truly the preferred procedure given that both strategies have similar likelihood
of being cost-effective at the chosen threshold.
6.1.2 Net Monetary Benefit of OPCAB versus Comparators in Multi
vesse! or Single-Vessel Disease
The value of the costs and effects can be converted onto a single monetary scale using the
principle of net monetary benefit (NMB). When a threshold WTP is chosen (ie, 50
000$/QALY in our example), the effects in QALYs can be converted to the value in dollars
by multiplying the estimated effect by die WTP. Given the value of benefits in dollars, the
difference benveen the benefits valued in dollars and the costs required to achieve those
benefits is equal to the net monetary benefit of the intervention. (Briggs 2002). Using this
technique, the net monetary benefit (NMB) for average-risk patients with multi-vessel
disease was estimated to be 340 864$ (95%CI 155 834 to 453 425$) for OPCAB and 325
680$ (95%CI 322 330 to 441 304$) for CCAB, and the incremental net monetary benefit
(INMB) was estimated to be 3234$. Therefore, when OPCAB is performed instead of
CCAB, die health care system benefits by a value equivalent to 3234$.
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For patients with single-vessel disease, the NME for OPCAB vas 371 643$ (95°/0CI 155 278
to 486 352$) and for PCI it was 373213$ (95%CI 146 965 tu 490 405$). The incremental net
monetary benefit was estimated tu be 1579$ for choosing PCI instead of OPCAB in patients
with single vessel disease. Therefore, the net benefits tu the health care system when
choosing PCI instead of OPCAB is estimated to be over 3000$.
6.1.3 Expected Value of Perfect Information (EVPI)
The expected value of perfect information (EVPT) is defined as the theoretical maximum
worth to the decision maker of additional information that is absolutely unerring about
uncertain states of nature (CADTH 2006). Estimates of EVPI reflect the economic return
on investment in furtlier research to purscte more information regarding an intervention and
its comparator. For OPCAB versus CCAB in multi-vessel patients, the expected value of
perfection information was calculated to be 1997$, assuming a societal willingness to pay
of 50 000$. For OPCAB versus PCI in single vessel disease patients, the EVPI was
estirnated to be higher, at 4850$.
Analysis of EVPI can pruvide a measure of the expected payoff from proposed research,
which can be used tu set priorities in researcli and development and help define when a
daim for a new technology should be deemed substantiated and when evidence should be
considered sufficiently competent and reliable tu indicate when it is not cost-effective (even
futile) tu gather any more information (Claxton 2001).
For OPCAB versus CCAB, EVPI analysis suggests that no more than appruximately $2000
per QALY gained or $5000 per QALY gained should be spend in order tu ascertain perfect
information. The interpretation of this EVPI needs tu be interpreted in light of the number
of ellgible patients to whom the intervention applied and tu the cost of the research required
tu achieve additional information. For example, if 25,000 patients are expected to undergo
bypass surgery each year in Canada, the additional value of 1997$ may be projected tu
deiver a payoff in net monetary benefit of, for example, up tu 20 million dollars. This
benefit may be worthwhile if the investment in research tu achieve that uncertainty reduction
requires less than 20$ million. However, this investment should be considered alongside
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other potential investments in research, in order to minimize the opportuniry cost of
choosing one course of research over another wHch may provide greater net payoff. In
particular, the expected payoff from a program cf research to reduce key uncertainties
regarding the role of OPCAB versus PCI in single-vessel revascularizations would be
expected to provide a return on investment that is several-fold higher given the number of
potentially eligible people and the greater value of EVPI for this decision. Therefore, from a
policy perspective, further research addressing OPCAB verscis PCI should be prioritized
above further research addressing OPCAB versus CCAB.
Exploration of EVPI evokes questions about whether more information is worthy of our
resources to attain. This issue has been raised before regarding OPCAB versus CCAB
(Cheng 2005). Despite the questionable role of further studies, there remain a number of
trials ongoing (Table XV). Perhaps these studies are warranted if they address the areas of
greatest likelihood to change decision maldng. However, evaluation of the outcomes in these
ongoing trials suggests they are focused on areas not likely to be the most efficient use of
limited research resources. In particular, ail identified ongoing triais were of OPCAB versus
CCAB, and not OPCAB versus PCI. In addition, examination of the outcome measures in
these trials reveals that areas of greatest contention are being addressed in only 1 trial each:
NINDs trial will evaluate NCD at 6mos, and DOORS trial will evaluate patency, QOL, and
cost-effectiveness at 6 months. Interestingly, the largest trial will provide more information
on areas where the least uncertainty exists: death, myocardial infarction, stroke and
reintervention.
Table XV: Oi OPCAB studies
Primary n D MI CVA Paten Retx NCD QOL CEA f/u
()utcome cv
ININUS trial Stroke andMj.) 340 X R Gin
2002 to 2005 at 6rnos
VA Study Death+Major 2200 / J X I X X X ly
2002-2007 rnorbidity A
30d
Death+MI+Ret
x at 1 yr
DOORS Death+MI+CV 900 I J I X I I
(ElderÎy A at 30d
70+).
2005-2011
“De[ined as deadi, repeat cardiac surgery, new technical support, cardiac arrest, coma, prolonged stroke, and/or renal
failure requiring dialysis.
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6.2 Strengths & Limitations
The results of thïs cost-effectiveness analysis should be interpreted in light of its strengths
and weaknesses. The methodology of this economic analysis performed in accordance with
the most recent iteration of the Canadian Agency for Drugs and Technologies in Health
Economic Guidelines (CADTH 2006), with the exception that the discount rate used in the
base case vas 3/o rather than 5%. Nonetheless, in sensitivitv analvsis allowing for die
discount rate to vary from O% to S%, the resuits did not materiaUy change.
This comparison of OPCAB versus CCAB or PCI was conducted on the framework of a
comprehensive meta-analysis of ah available randomized controlled trials(Cheng 2005,
Cheng 2006, Puskas 2005) Most of these trials provided intention-to-treat data, with
complete follow up. The randomization served to minimize the risk of selection bias that is
known to be inherent in obsenrational swdies of OPCAB versus CCAB (Cheng 2005,
Wijeysundera 2005). Multiple secondary analyses provided opportunitv to explore the cost
effectiveness across multiple perspectives, risk groups, and real world estimates.
While great care was taken to consuit authoritative sources for cinical probabilities, costs,
and utilities, there are certain shortcomings in our data that should be made explicit for
decision makers.
6.2.1 Probabifities
It is notable that longer term neurocognitive dysfunction was assumed to be unimportant in
low-risk single-vessel patients who were undergoing revascularization. This assumption was
made because the randomized trials to date have not provided measures of neurocognitive
dysfunction. This assumption is congruent with other randomized trials assessing
conventional surgical revascularization with PCI (Wahrborg 2004).
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It is also notable that most of the randomized trials in the meta-analysis of OPCAB versus
PCI involved the use of PCI with or without bare metal stents. Drug-eluting stents have
entered the market and have changed practice signfflcantly, potentially reducing the risk of
restenosïs and reintervention (Park 2003, Morice 2002, Moses 2003). Congruent with the
potential for improved dbnical outcomes with drug-eluting stents, secondary analysis of cost
effectiveness with the non-randomized trial of OPCAB versus PCI with drug-eluting stents
showed an improved ICER for PCI (refer to Table XIX).
Sïnce randomized trials did not aiways provide reilable probabilities for some important
outcomes over the longer term, there remains significant uncertainty regarding the relative
benefit beyond I to 2 years. For example, for OPCAB versus CCAB the overail relative risk
of neurocognitive dysfunction was reported in only a few trials and varied signiflcandy
amongst randomized trials for this endpoint at ail timepoints including 30 days, 3 months,
and up to one to two years. Nevertheless, sensitivitv analyses which allowed for variation
across very wide ranges of plausible probabilities did not materially affect die magnitude of
the net monetary benefit and the conclusions remained robust. The relative risk of stroke
and reintervention was also under-reported beyond two years (Cheng 2005).
As might be expected, the probabilities that had the most influence on die results of cost
effectiveness were die probability of stroke for both decision models, and the probability of
reintervention for die OPCAB versus PCI model. One-way sensitivity analysis of stroke for
OPCAB versus CCAB showed no possibility of CCAB becoming dominant over OPCAB,
given die plausible ranges of probabilities within the model. On the other hand, for OPCAB
versus PCI, the conclusions were integrally related to the probability of stroke. At a
threshold of stroke probability of I.8% for PCI, OPCAB would become die dominant
strategy. However, the likelihood of the risk of stroke exceeding this level is low as suggested
by the existing evidence base regarding stroke risk in patients undergoing PCI (Patel 2006).
As a result of the uncertain and largely unmeasured differences in OPCAB versus its
alternatives beyond one to two years, this model assumed that there would be no remaining
differences between strategies after this time. Whether or not this is a true reflection of the
relative benefits remains to be proven.
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Partial EVPI calculations can quantify the value of learning about particular subsets of
uncertain parameters in decision models (Claxton 2001). While estimation of expected value
of perfect partial information was beyond the scope of this analysis, it is likely that the areas
of greatest uncertainty which would provide the most efficient use of research resources for
future studies of OPCAB would include the long term risk of NCD, stroke, and
reintenrention.
6.2.2 Costs
The baseline cost of OPCAB, CCAB, and PCI were estimated from our local hospital
databases. As a result, they will reflect our local practices and patient population. In addition,
for the OPCAB cohort, a relatively small cohort was available to estimate costs since isolated
OPCAB is performed less commonly than CCAB. Patients who were undergoing hybrid
procedure with robotic surgery were eliminated from the OPCAB cohort, further reducing
the sample size. Despite these limitations, the estimates of OPCAB, CCAB, and PCI costs
were congruent with estimates published elsewhere (Lamy 2006, Yock 2003).
A number of costs were not considered, including the cost of training new and existing
surgeons for OPCAB. The incremental cost of training should not be underestimated, given
the advanced sldll required relative to training for conventional surgery on the still heart or
for PCI. In addition, some cost estimates were unknown and constituted informai estimates
given by health professionals at our institution, or extrapolation from other related areas.
For example, efforts to quantify the cost of neurocognitive dysfunction reveaied no relevant
published literature. As a result, estimates were based on professional opinion in comparison
with the cost of transient ischemic attack.
In quantifying the incremental costs associated with complications was derived from a
variety of sources. In Canada, lCD-10-CM procedure codes are abstracted from the patient
medicai record by medical record technicians. The presence of a code signifies whether the
procedure was performed but not how often the procedure was performed. In addition,
patients may experience more than one adverse event, and separating the costs for each
complication is complex. Assigning and validating administrative data codes for each
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technology profile for our study would have required chart review and significant resources.
Although ideal, tHs was considered to be outside the scope of this paper. Future work in this
area at our institution may provide opportunity to improve the estimates in this model.
As expected, the lifetime costs of surgical and percutaneous revascularization were lower
than that reported in the United States (Hlatky 2004); however, the increased cost of
OPCAB relative to PCI was congruent with published estimates for both the in-hospital
costs and the lifetime costs. Underestimation may have been related to the combined effect
of our conservative assumptions.
6.2.3 Utilities
Since direct aggregation of QALY estimates was not possible from the available randomized
trials of OPCAB due to the short timeframe of the trials (1 year) and due to the multiple
dimensions, scales and timeframes of measurement, utility estimates were derived from a
number of published sources. There was heterogeneity across these sources in how the
utilities were derived, possibly introducing bias. That the estimates of incremental QALYs
gained for OPCAB versus CCAB were smafl is congruent with shorter term estimates of
QALYs from randomized and non-randomized trials of OPCAB versus CCAB, which
suggest small (if any) differences are possible (Al-Ruzzeh 2006, Ascione 2004, Immer 2003,
Ivlontallebzadeh 2006, Nathoe 2003, Puskas 2004). \Vhile the small incremental gain in
QALY for OPCAB versus CCAB in this analysis, when considered in isolation, would not
be statistically or cinically significant given the small absolute differences found, it could be
argued that even small differences may be worth ascertaining in the field of cardiovascular
surgery given the large volume of patients that undergo surgery worldwide. Small differences
in QALYs projected over 1 million CABG surgeries performed worldwide may result in
cinically tangible gains in outcomes over a population. Nonetheless, given the lack of
certainty in our model and the wide overlappïng confidence intervals for QALYs gained for
OPCAB and CCAB, we cannot be sure that the small estimated differences are real. Further
longterm research will be required to determine whether scistainable differences exist in
dllnical outcomes. Since our model assumed that differences in clinical outcomes \vould ont
persist beyond 2 years (the maximum reach of the evidence base at the time of preparation
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of thïs decision analysis), our estimates will be conservative if future trials demonstrate
persistent benefits over the longterm.
The estimates of incremental QALYs gained for PCI relative to OPCAB were incongruent
with the extensive published literature of conventional surgical CABG versus PCI which
suggests signifïcandy increased QALYs with surgical revascularization than with PCI over
the longer term. (Borkon 2002, Hlatky 2004, Mercado 2005, Wahrborg 1999). Randomized
trials of OPCAB versus PCI also suggest a trend toward improved QOL with OPCAB as
early as one year post-procedure (Eefting 2003, Reeves 2004). The discrepancy between the
estimated QALYs gained in this decision model relative to other pciblished Uterawre may be
due to the higher relative mortahty rate observed in the OPCAB group compared with the
PCI group, wHch may have reduced the total projected quantity of life sufflciently to affect
QALYs. This increased relative mortality in the OPCAB group was also at odds with the
pubflshed literature, which suggests improved survival in those treated with surgical
revascularizadon relative to those treated with PCI. Nevertheless, these latter trials compared
CCAB to PCI, and their generalizability to OPCAB may be questioned. Overail, the trend
toward differences in mortality between OPCAB and PCI should be interpreted with caution
as it is based on inadequate sample size (6 randomized trials; 949 patients) to provide precise
estimates of the rare outcome of mortaliry.
Despite these limitations and caveats in interpretation of QALYs, in both decision models
no amount of variation in utilities across the defined ranges resulted in changed conclusions.
OPCAB rernained dominant over CCAB, regardless of utility estimates. For OPCAB versus
PCI, the preferred strategy remained constant over the plausible range; however, the cost
effectiveness ratio became more attractive at higher post-procedure utilides for PCI.
It is known that the choice of approach for obtaining utihty scores may signiflcantly impact
the estimate of the gain in health related quahty of life for pre- and post-surgical assessments
in cardiovascular surgery (Feeny 2004). Research suggests that the value of a QALY can
change radically according to what scale is used, how the questions or scale is presented, and
who is making the choices and the values assigned may not aiways reflect the values of
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patients receiving the interventions Malek 2001). finally, QALYs are Hkely to undervalue
health care because they do flot capture the xvider benefits (externalities) which may be
gained, for example, by a patient’s family and friends.
Although there are controversies surrounding die use of QALYs, this does flot suggest that
they should be completely eliminated as an outcome measure. QALYs provide the best
attempt so far to solve the problem of measuring health care outcomes (Office of Health
Economics 2006). Using QALYs is currendy the dominant and most widely-accepted
method of capturing mortality and morbidity in a single unit, and is endorsed by health
economists and HTA units worldwide. QALYs can aid efficient and equitable resource
allocation, but only as a part of a discussion that encompasses wider health-related needs as
well as societal, cultural and dinical values.
6.3 Genefalizabliity
When cost-effectiveness analysis is performed, the intention is to inform decisions within a
specified region. Given that costs are inextricably dependent on locale, it is difficcdt to
ensure that economic analyses are sufficiently generalizable to areas outside of its region of
focus. In this analysis, costs were derived from two important sources, and applled in
accordance with the perspective of die analysis. For the base case analysis, costs were
preferentially chosen to be most representative of the broader health system in Canada.
Therefore, the base-case analysis should lie considered generalizable across Canada.
Similarly, for the societal perspective, Canadian sources were used to increase the
generalizabilitv. However, for the institutional perspective, the costs were generallv derived
from institution-specific sources, and the genera]izability may be dependent on local
institudonal patterns. In particular, discharge protocols and surgeon expertise in provision of
OPCAB may change cost-effectiveness consideradons from the local institudonal
perspective.
The esdmated probabilides of clinical outcomes were often in Une with those reported in
real-life observational studies. In addition, the ranges explored during sensitivity analyses
incorporated the probabilities found in observational trials, ificreasing the likelihood that this
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analysis and its conclusions are generalizable across diverse ranges of probabilities, across
many settings, and across multiple perspectives.
6.4 Implications for Decision-Maldng
Decision analysis is defined as the application of explicit, quantitative methods to analyzing
decisions under conditions of uncertainty (CADTH 2006). The process of decision analysis
attempts to make fully explicit ail of the elements of the decision, ideally including cinical
outcomes, quality of life, and costs. Decision analysis modeling can help to systematically
assess alternative courses of action if the expected value of each relative to the other is
unclear.
On their own, decision analysis and cost-effectiveness analysis are insufficient for
considering any new procedure or technology in healthcare. Other considerations must also
be taken into account, including considerations from social, ethical, legai and political
domains. In light of these interposing domains of influence on decision-making, it becomes
increasingly apparent that decisions of importance in healthcare do not lend themselves to
simple decision rules (Rawlins 2004).
Most decisions about health technologies and interventions require tradeoffs between costs
and effects. Whether the effects are worth the cost depends on whether the ICER is less
than the decision maker’s willingness to pay for those effects. (Hoch 2006) A societal WTP
of 50 000$/QALY is most often quoted as a potential threshold; however, in reality this
threshold is not known. Studies of decision-making have suggested that there is no single
value ofWTP that applies to ail decisions (Devlin 2004, Hirth 2000, Neuman 2005). Factors
unique to each decision, such as equiry and other social, ethical, and political considerations,
wiil raise or lower die bar on WTP for new interventions. For cost-effectiveness analyses to
be relevant for decision maldng, results must have meaning for decision makers with
different decision thresholds and different WTP. The cost-effectiveness acceptability curve
describes the probabiiity that an intervention of interest can 5e considered cost-effective
across differing thresholds of WTP (Briggs 1998; Hoch 2006; Lothgren 2000; Fenwick
2000). Examination of the cost-effectiveness acceptabilicy curves provides a useful
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framework for considering implications for decision making that should resuit from this
cost-effectiveness analysis.
6.4.1 Multi-vessel Disease in Average-Risk to High-Risk Patients
Since the dominance of OPCAB relative to CCAB is constant across ail definitions of
WTP, OPCAB should be recornrnended with confidence for uptake into routine practice,
across the risk spectrum of patients with multi-vessel CAD. The knowledge that OPCAB
is cost-savings and that it is applicable to high risk patients is poignantly relevant in our
health care system where resource constraints are growing while the risk profile of
patients presenting for surgical revascularization is rising (Ivanov 1998).
6.4.2 Single Vesse! Disease in Low-Risk Patients
The preferred strategy for patients with single-vessel disease is less clear. Overail, given our
imperfect information and range of assumptions, it appears that PCI has a higher probability
of being cost-effective than OPCAB. Nevertheless, if WTP is increased above 55
000$/QALY, OPCAB ma be the preferred strategy.
6.5 Implications of Changing Practice Patterns
This analysis was constructed in two separate decision trees since patients eligible for CCAB
and PCI represent two different patient cohorts. Nevertheless, as technology, technique,
skills, and knowledge have progressed, the demographics of patients who are considered
eligible for CCAB and PCI has changed. Wbile this analysis considered two separate
scenarios for multi-vessel and single vessel disease, the limes are increasingly blurred between
who is eligibÏe for CCAB versus PCI. More recendy, with the development of advanced
surgical techniques and technologies such as drug-eluting stents, it is increasinglv apparent
that CCAB and PCI are no longer mutually exclusive alternatives. Higher risk patients, with
multi-vessel CAD, sometimes with difficult morphologv, are increasingly considered to be
eligible for PCI. Patients are choosing PC1 preferentially to CCAB due to the decreased
invasiveness of the procedure and improved post-procedure recovery time, in spite of the
knowledge that CCAB may produce more durable results. Some patients choose PCI, with
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the intention of eventually moving to CCAB if PCI fails. As a resuit, the consideration of
OPCAB versus CCAB and PCI may eventually become amenable to a single decision tree.
In addition, the probabilities will need to be reconsidered and updated within the current
model as practice patterns and demographics change. New technologies and techniques,
such as total arterial revascularization, robotics, and drug-eluting stents, may become
important enough to cause re-evaluation of the relative cost-effectiveness of OPCAB versus
PCI or OPCAB in the context of these new technologies, or may entirely change the
relevant set of comparators (ie, hybrid procedure combining OPCAB with PCI). However,
any proposed program of research should be subjected to the rigors of EVPI analysis, and
funding agencies should provide prioritized funding to areas where reduction in uncertainty
is likely to provide a payoff in net monetary benefits that is sufficiendy worthy ofits research
costs.
6.6 Broader Canadian and International Considerations
6.6.1 Canadian Considerations
Cardiovascular diseases ai-e the major cause of mortality in the Western world, and it is
expected that this will remain 50 during die foreseeable futctre. As this situation also
becomes increasingly true for developing countries, its scourge wlll exact an unfathornable
toll on the health care system and societies around the globe. lmproved efficienc in surgical
and non-surgical management of CAD is of paramount importance as even small changes
will escalate to large absolute dilnical, economic, and humanistic impacts when projected
across the millions eligible for coronary intervention worldwide.
In Canada, and elsewhere around die world, knowledge that OPCAB is dominant over
CCAB should provide impetus for a significant increase in uptake of off-pump surgical
techniques. Currendy, in some centres the number of cardiovascular surgical procedures
performed in off-pump approaches 100% (Mika 2004, Roy 2001) whule in others, off-pump
technique is not provided, or applied only to select patient groups. Overali, the potential
benefits of OPCAB lias led to 2O% of ail surgical revascularizations being performed off
pump in North America and Western Europe, and an estimated 25% of ail
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revascularizations worldwide (Mack 2000, Visudharom 2003). In Canada, only 16% of
procedures are performed off-pump (Desai 2004).
The iow rates of OPCAB provision raises questions about whether patients are being denied
a procedures that may improve their quality of life and also release more resources into the
health care system for more efficient use. Since OPCAB provides this potential benefit at
substantially reduced costs, efforts should be focused on facilitating its uptake and
minimizing the lag time required bv the learning curve. Policy makers should consider
reformulating reimbursements to hospitals to favour OPCAB rather than CCAB, and
inducements through grants to purchase stabilizer technology and train surgeons should be
considered. In addition, accreditation of surgical trainees and established cardiovascular
surgeons alike should be contingent on technical expertise in OPCAB in the current era.
Nonetheless, ail of these policy considerations will need to be assessed in the local political
construct, and will need to be implemented in collaboration with experts in the field to
ensure adequate time to build OPCAB programs.
A recent international consensus conference, after systematic review of the available
literature regarding OPCAB and CCAB, concluded that OPCAB should be recommended to
minimize morbidity and resource utilization in tvpical patients undergoing surgical
revascularization, and should also be considered in high-risk patients (Puskas 2005). Given
the low rate of uptake in Canada, much effort will be required to make the change from the
established ‘tried and true’ on-pump procedure to the innovative procedure.
Often technologies and techniques that are heralded as new and improved risk being
prematurely taken up Ïnto practice without the support of the evidence and supporong cost
effectiveness analyses. In this case, a less common scenario lias arisen, wherein a new
technique that has been proven as more efflcacious and less cosdy with supporting meta
analyses and cost-effectiveness studies, lias met with resistance to uptake.
Reasons for lagging uptake, and for waning interest are not precisely known. Altliough, tliere
is speculation that the siope of the uptake cunre lias been lower than predicted due to
remaining uncertainty about the robustness of grafts over time (Khan 2004), and due to the
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lack of definitive proof of durable impact on NCD or lower than expected impact on stroke
and mortality. Considered individually, it is true that RCTs have shown varied resuits for
neurocognitive decine - an outcome that is hard to define and even more difficuit to
measure. However, considered in aggregate, the weight of the evidence suggests that there
may be benefit, at least over the short to midterm, and there is likely no harm. Regarding
graft patency, some studies have shown graft patency to be similar at follow-up for OPCAB
and CCAB (Puskas 2004), while I<}ian et al showed significandy reduced graft patency for
OPCAB within 3 months after surgery (Khan 2004). Critics of the study by Khan and
colleagues point to the fact that their surgeons were performing OPCAB early in the learning
curve, and other studies showing no compromise in graft patency have involved surgeons
with extensive experience in OPCAB (Puskas 2004). Some surgeons are also concerned that
when a revascularization procedure is performed off-pump, surgeons tend to do fewer grafts
than they wouid if the patient is undergoing CPB (Cheng 2005). A recent survey of Canadian
surgeons revealed that the two most influential factors preventing uptake of off-pump
surgery were concerns regarding incompiete revascularization and perceived Yack of proven
cinical benefit (Desai 2004). Another potential reason that lias not been discussed in the
literature is the toil that is taken on surgeons who perform OPCAB, which requires extreme
attention and unpredictable conditions whiie operating on a moving field.
In the absence of clear guidelines to define the standard of practice, individual surgeons are
ofren left to make decisions on their own regarding uptake of a new technoÏogy or
technique. The range of proportions of CABG surgeries performed off-pump in centres is
clear evidence that a standard does not exist. Since complication rates seem to be lower with
OPCAB, most experts wiii agree that ail else being equai, it is beneficiai to avoid CPB.
However, “ail else being equal” has flot yet been definitively proven for the most
contentious points of debate in this field — in particular, longterm graft patency, and NCD.
Yet, evaluation of EVPI suggests that pursuing validation of “ah else being equal” is flot
without a ceiling willingness-to-pay, and the limit in expected value that will accrue from
further knowledge may not significantiy add to what we already know.
Increasing competition by innovations in other areas of cardiology may provide the impetus
needed to increase the uptake of OPCAB by cardiac surgeons for multi-vessel disease.
Increased rates of PCI in Canada and die subsequent decrease in coronary artery bypass
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grafts are slowly eroding the need for cardïac surgeons and shortening some provincial
waiting times. The Canadian Institute for Health Information and Statistics Canada report a
2.8% decrease in CABG rates and a 66% increase in the number PCIs or angioplasties
performed across Canada between 1998—99 and 2002—03, and the American Heart
Association reports a similar trend south of the border (Sibbald 2005). While this pressure
may spur appropriate uptake of OPCAB for multi-vessel disease, die same pressure could
resuit in increased single-vessel disease patients being treated surgically. This highlights the
need for increased vigilance on practice patterns in light of future research on OPCAB
versus PCI. It also higliliglits the need for preferential funding of OPCAB versus PCI
studies.
6.6.2 International Considerations
In developing countries, the knowledge that OPCAB is cost-savings relative to CCAB, and
that either OPCAB or PCI are options for single-vessel disease will be welcome. This
knowledge supports their current practice patterns, where OPCAB is more prevalent than in
developed countries with improved access to CPB. If the resuits of the cost-effectiveness
analysis had been different (ie, CCAB cheaper and more effective), the uptake into practice
would have been more difficuit given the upfront resources that would be required to
purchase and support CPB technology.
In developing countries, the knowledge that beating heart surgery is not only cheaper, but
also more effective, may help to break down earlier misconceptions that this approach to
surgical revascularization is flot ‘cheap and inferior’ or ‘backward’ and ‘archaic’, but rather
represents a significant progress in technology and technique (Benetti 2002, Buffolo 2006).
The credit for this breakthrough should be given to those in developing nations who
persevered in providing CABG on the beating heart in constrained and professionally
volatile circumstances
— a practice that developed flot only out of necessity due to lack of
CPB resources, but also out of die sheer desire for valid scientific development of a
promising
- but often misunderstood
- technique. Indeed, their perseverance toward IOO%
provision of off-pump revascularization lias undoubtedly resulted in die release of significant
health care resources for other (better) uses. This latter point should not lie taken lightly in
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the context of an extremely constrained health system in the developing world, where the
opportunity cost of preferential provision of on-pump CABG would have been experienced
more acutely.
6.7 Overail Implications
Off-pump coronary artery bypass surgery lias experienced a renaissance since the earÏy
1990s. However, the renaissance bas been far from unconditionafly accepted, and only 16-
25% of potentially eigible CABG procedures performed off-pump. With its progression
along the innovation curve, two schools of thought have emerged (Ascione 2001, Cheng
2005).
Those in favour of OPCAB emphasize the potential for reducing morbidity and cost whule
concomitantly allowing undeveloped countries to provide a program of coronary surgery
that was previously unattainable (Ascione 2003). A second school of thought is held by those
who raise sefious concerns regarding the potential for suboptimal anastamoses, ofwhich the
implications cannot be sufficiently measured undl sufficient rime bas passed with adequate
followup of randomized trials. This latter school of thought also warns of the unique
challenges presented by the protracted learning cunre required to train and maintain
surgeons’ skills for OPCAB. The result is a significant divergence in the treatment of
patients, often even within the same hospital, the impact of which may be profound
(Ascione 2003).
In light of the current evidence and economic analysis, this discrepancy in rates of uprake
should be addressed urgendy considering the degree of quality of life and health care
resources at stake. The opportunity cost of allowing individual surgeons to lie the
gatekeepers of thïs valuable technique bas become too great to allow for continued
unfostered evolution of its progression along the innovation-uptake curve in Canada.
Policymakers should facilitate individual surgeons and institutions in defining the role of
OPCAB relative to conventional revascularization.
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6.8 Conclusions
For multi-vessel disease in average to high risk patients, OPCAB appears to be a cost-saving
alternative to CCAB across multiple perspectives including the health care system, the
institution, and society as a whole. For single-vessel disease in low-risk patients, PCI may the
preferred alternative to OPCAB, although significant uncertainty remains for the latter.
On the basis of these resuits, OPCAB should be recommended as an efficient use of
resources in Canada for multi-vessel disease, and suppordng policies should be put into
place. For single-vessel disease, PCI may be recommended; although, further research
should be considered to reduce uncertainty regarding the role of OPCAB versus PCI in this
population.
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APPENDIX A
Pubmed Search Strategy for Systematic Review of OPCAE Cost Studies
No. Search Terms Citation
Hits
I Search cost* OR economic* OR costeffective* OR 517188
cost-utffity OR resoufce*
2 Searcli “models, economic”(MeSH). 4772
3 Searci “coronary artery bypass, off-pump”(MeSH). 458
4 Search “pefcutaneous coronary intervention” OR 2191
“angioplasty”
5 Search (#1 OR #2) AND (#3 OR #4) 19
6 Search (“off-pump” OR “off pump”) AND coronary 92
AND (#1 OR #2)
7 Search #5 AND #6 92
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APPENDIX B
Identification of Eligible Trials for Literature Review
Potentially relevant
citations identified and
screened for retrieval
(n92)
______________
Citations excluded (n=55)
• Non-comparative, n = 7
• Comparative, but studying
extraneous interventions (ie,
antifibrinolytics in OPCAB y
CCAB),n=9
• NoOPCAB,n=lO
• Costs flot reported, n=16
Citations retrieved for
• Hybrid procedure, n=I
more detailed evaluation
• Secondai-y reviews of existing cost(n=37) analyses, n=12
Citations excluded after review (n= 12)
No costs reported, n = 12
Potentially appropriate
studies to be included in
the meta-analysis
(n=25)
Studies excluded from the
systematic review, (n=2)
• Duplicate data, n=l
• Unavailabte, n = 1
Studies with usable
information included in
systematic review
(n23)
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APPENDIX G
OPCAB versus CCAB Decision Tree fufly Expanded
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APPENDIX H
OPCAB versus CCAB Tree with One Markov Heahh State Expanded
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APPENDIX I
Reintervention Subtree
Stroke
Stroke
Stroke
Sure
ReinteRention
Stroke
p Re j nte rventio n2
Pers ist
# #
#
Stroke
pDie3O Death
APPENDIX J
Costs for OPCAB versus CCAB Model
19323 LHSC
10432 - 28214
CCAE* 21097 LHSC
(10549 - 42194)
Acute post- pAF*cAcuteAf + pAngina*cAngina + pIABP*cIABP +
operative plnotropes*clnotropes -I- pMIcAcuteM1 + pRenalFai]ure*cRF +
Complications pReThoracotomy*cRethoracotomy + pResplnfection*cResplnfection +
pTransfuse*cTransfusion +pMediastinitis*cMediastinitis
Atrial Fjbrillation 9916 Cheng 1996
(4958
— 19832) Taylor 1990
Myocardial 8228 Cheng 1996 Taylor 2000
Infarction (4114
— 78481)
Acute NCD 2000 Taylor 1990
(1500 2500)
Acute Stroke 13291 Cheng 1996, Sinclair 2001
(6646
— 6476$) Taylor 1990
AngÏna 3323 Professional Opinion
(1000-1500)
Follow-up” 1488 Cheng 2003
(1378— 1598) Lamy 2006
IAEP 21114 Taylor 1990
(10557
— 42228)
Inotropes 1113 LHSC
(500
— 2300)
Mediastinitis 36287 Hollenbeak 2000, Taylor
(10423—28214) 1990
Late NCD 100 Opinion
(500
— 2000)
Post-procedure” 1000 Opinion
(500
— 2000)
Reintervention 21097 Same as CCAB
(1 0549
- 42194)
Respfratory 40717 Cheng 1996
Infection (20359
— 81434) Taylor 1990
Rethoracotomy 4852 Yock 2003
(2426
— 9704)
Renal Failure 22996 Cheng 1996
(11498_45992)
Transfusion 474 Canadian Blood Services
(350-550)
Post-Stroke 15177 Anis 2006
(7680
— 30720)
AF=atrial fibrillation, C=cost; LHSC=London Health Sciences Centre (ouf institution); M1 Myocardial
infarction, NCD=neurocognitive dysfunction; pprobabiity
Costs associated with the surgery theatre time, supplies (including the stabilizer technology and disposables for
OPCÀB), anti Iength of stay including overhead costs and depreciation, plus die cosi of professional fees paid b’ die
Ministry ofHealth (MOH) ofOntario, were included in the cost esumates. ‘‘Professional fees paid by the MOH wcre
includcd
Cost of transfusions vas considered relevant onlv to the health care svstern (Base Case Analysis) and societal
perspective since institutions do no pay for blood products &rectly
Event OPCAB CCAB References
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Appendix K
Productivity Loss Estimates
Event Assumed Duration Off Work Estimated Reference
productivitv h)SS
(2004 CAD)*
Mortality Ufetime 28 750 Statistics
(conservadvely assigned I Canada, 2005
year Ioss)
Stfoke 6 months 14 375 Professional
opinion
AMI 3 months 7 188 Professional
opinion
PCI 3.5 months $385 Pocock 1996
CCAB 5.5 months 13 177 Pocock 1996
OPCAB 5.5 months 13 177 Pocock 1996
*Assuming ail patients in the cohort are employed, at an average 2004 wage for
elderly of 28750$ (assuming cohort of22% females)
$3
APPENDIX L: Types of Costs Included fof Varying Perspectives
Costs Included
Direct non-Ï]eatth care
coi-ti
Direct hea/th care
‘ystern costs
Direct costs topatients
andfamiÏies A
Proditctit’ii’ cosis
Description
Social services, sucli as home help, meals
on wheels, disability benefits
Drugs, medical devices, equipment,
facilities, and associated overhead costs,
appliances / supplies paid by government,
health care providers’ wages, Health
care providers and other staff,
Rehabilitation in a facility, home care.
Long-term care in nursing home
Out-of-pocket payments (including co
payments) for drugs
Lost productivity due to reduced
working capacity, or absence from work.
(Base
Case)
Secondary
Analyses
ANote: Time costs to patients and families for traveling, and work time lost by family
membcrs providing care to the patient were not included. Reference: CADTH 2006
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APPENDIX M
Probabifities for OPCAB versus CCAB Model
AcuteAtrial 1 0.176 0.268 Cheng 2005
Fibrillation (0.1557 — 0.1983) (0.2432-0.2935)
Mediastinitis, 0.031 0.054 Cheng 2005
Wound (0.0208 — 0.041 9) (0.0369 — 0.0635)
Complications
Respiratory 0.05 0.16 Cheng 2005
Infection (0.0306 — 0.0834) (0.1216 — 0.2078)
Angina 0.065 0.076 Cheng 2005
(0.0441 — 0.0947) (0.0532 — 0.1075)
IABP,3Odays 0.011 0.010 Cheng 2005
(0.0049 — 0.0231) (0.0039 — 0.0212)
Intropes, 30 0.151 0.236 Cheng 2005
days (0.1281 — 0.1763) (0.208 — 0.2666)
AMI, 30 days 0.020 0.028 Cheng 2005
(0.0136 — 0.0289) (0.0203, 0.0382)
Renai. Failuxe 0.009 0.021 Cheng 2005
(0.0042 — 0.01 98) (0.0123 — 0.0341)
Transfusion, 0.284 0.425 Cheng 2005
30d (0.2599 — 0.3103) (0.3975 — 0.4537)
Re- 0.017 0.022 Cheng 2005
Thoracotomy (0.0105 — 0.0259) (0.01 52— 0.0328)
for Bleeding
Remtervention, 0.010 0.01 Cheng 2005
30d (0.0024 — 0.0216) (0.008 — 0.0307)
Reintervention, 0.029 0.016 Cheng 2005
(0.0173 — 0.0463) (0.008 - 0.0307)
Stroke, 2y 0.011 0.023 Cheng 2005
(0.0425 — 0.0277) (0.012 — 0.0426)
Stroke, 30d 0.004 0.01 Cheng 2005
(0.0017 — 0.0094) (0.0057 — 0.0165)
Neurocognitive 0.400 0.506 Cheng 2005
Decline, 30d (0.3258 — 0.4717) (0.4307 — 0.5811)
Neurocognitive 0.270 0.309 Cheng 2005
Dedine, 2y (0.2266 -0.3626) (0.2435 — 0.3 834)
Persistent NCD, 0.42 0.42 Newman 2001
after2y (0-0.60) (0-0.60)
Death, 2 years 0.023 0.026 Cheng 2005
(0.013 — 0.0392) (0.01 57— 0.013)
Death, 30 days 0.012 0.010 Cheng 2005
(0.0062 — 0.0168) (0.0063 — 0.0171)
Age 63 Cheng 2005
(50—75)
Years 20
(2—20)
Discount 0.03 (0-0.05) Garber 1996
Event OPCAB CCAB References
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APPENDIX N
Utifities for OPCAB versus CCÀB Model
Event OPCAB CCAB References
Acute Stroke 0.31 0.31 Sinclair 2001
Utility (0—0.90) (0—0.90)
Post Stroke 0.75 0.75 Sinclair 2001
Utffity (0—0.90) (0—0.90)
Acute NCD 0.02 0.02 Phillips-Bute 2006
Utility
Reduction
NCD Utffity 0.75 0.75 Phiilips-Bute 2006
(0.50
— 0.90) (0.50
— 0.90)
Pre-Procedure 0.72 0.72 Puskas 2005
Utffity (0.5—0.9) (0.5—0.9)
Post-Procedure 0.80 0.80 Puskas 2004
Utility (0.6—1.0) (0.6—1.0)
NCDzneurocognitive dysfunction
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APPENDIX O:
Probabifities for Risk GrouDs
Outcome OPCAB CCAB
Death, 30d
2.8 4.7
Ail Hi Risk Pts
LVI) 3.7 6.8
Elderly 4.1 5.6
Left Main 1.1 3.2
Diabetics 2.8 3.6
Renal Dysfunction 2.4 7.2
Euroscor5+ 2.6 7.1
Multiple risks 2.6 3.8
Aorta, atheromatous 5.1 8.5
Redo/Urgent 4.1 6.7
COPD 0 2.6
AMI, 30d
Ail Hi Risk Pts
LVD
2.1 2.9
Elderly
Left Main
Diabetics
Renal Dysfunction
Euroscor5+
Multiple risks
Aorta, atheromatous
Redo/Urgent
COPD
1.4
1.6
0.7
1.6
1.6
4.4
1.6
3.6
2.4
O
1.6
4.0
1.4
1.8
2.8
10.0
1.9
7.8
3.6
5.6
Ail Hi Risk Pts
Stroke, 30d
0.9 2.1
LVD
Elderly
Left Main
Diabetics
Renal Dysfunction
Euroscor5+
Multiple risks
Aorta, atheromatous
Redo/Urgent
COPD
0.9
1.0
O
1.0
1.9
0.4
0.5
4.3
1.0
O
0.8
6.6
0.3
2.1
8.3
2.0
1.6
6.9
2.7
2.3
$7
APPENDIX O. continued
Probabifities for High Risk Groups
Outcome OPCAB CCAB
AF, 30d
Ail Hi Risk Pts 18.3 23.0
LVD 14.1 17.7
Elderly 30.4 45.9
Left Main 9.7 15.8
Diabetics 15.8 23.2
Renal Dysfunction 26.3 26.9
Euroscor5+ 20.0 22.1
IViultiple risks 15.9 21.9
Aorta, atheromatous
-
-
Redo/Urgent 26.4 25.4
COPD O O
Transfusi )fls
Ail Hi Risk Pts 34.5 55.6
LVD 36.7 52.7
Elderly 47.8 76.6
Left Main 34.1 57.2
Diabetics 36.2 55.9
Renal Dysfunction 52.3 68.4
Euroscor5+ 15.4 17.3
Multiple risks 34.5 55.1
Aorta, atheromatous
-
-
Redo/Urgent 0 4.0
COPD 18.2 48.4
Renal Dysfunction, 30d
Ail Hi Risk Pts 4.5 4.6
LVD 3.7 7.2
Elderly 2.7 4.8
Left Main 2.1 1.6
Diabetics 1.9 2.8
Renal Dysfunction 8.6 18.2
Euroscor5+ 15.3 6.9
IVIuldple risks 2.7 3.9
Aorta, atheromatous 2.4 6.4
Redo/Urgent 3.5 7.4
COPD 3.0
____
4.7
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APPENDIX O, continued
Probabifities for Risk Grouvs
Outcome OPCAB CCAB
Pulmonarv/Respiratorv Cx
Ail Hi Risk Pts 5.0 5.2
LVD 16.6 15.4
Elderly 8.6 5.3
Left Main 1.7 3.4
Diabetics 1.3 1.8
Renal Dysfunction 9.8 16.8
Euroscor5+ 7.6 5.4
Multiple risks 4.6 7.7
Aorta, atheromatous
-
-
Redo/Urgent 4.0 2.1
COPD 0 12.5
Inotropes
Ail Hi Risk Pts 21.3 28.6
LVD 76.6 91.4
48.0 19.3
Elderly
Left vIain 16.6 39.6
Diabetics
-
-
Renal Dysfunction 13.7 32.2
Euroscor5+ 8.0 4.4
Multiple risks 20.9 28.6
Aorta, atheromatous
-
-
Redo/Urgent
-
-
COPD 21.3 38.2
Mediastinitis /Wound
Infection
Ail Hi Risk Pts 1.4 2.1
LVD 0.8 1.0
Elderly 0.5 0.4
Left Main 0.6 0.7
Diabetics 3.0 3.2
Renal Dysfunction 0.5 6.1
Euroscor5+ 2.2 3.5
Multiple risks 1.1 1.4
Aorta, atheromatous 0.4 0.8
Redo/Urgent 8.5 9.6
COPD 2.5 0
APPENDIX O, continued
Probabifities for 1 Risk from Puskas 2005’)
$9
Outcome OPCAB CCAB
Reoperation for Bleeding
Ml Hi Risk Pts 2.2 3.3
LVD 2.7 4.1
Elderly 3.8 5.3
Left Main 0.6 2.4
Diabetics 1.7 2.6
Renal Dysfunction 4.0 4.5
Euroscor5+ 2.6 4.2
Multiple risks 1.8 2.8
Aorta, atheromatous 1.5 4.3
Redo/Urgent 4.4 4.4
COPD
IABP
AllHiRiskPts 1.9 3.9
LVD 3.4 3.4
Elderly 1.9 9.5
Left Main 1.6 1.5
Diabetics
-
-
Renal Dysfunction 6.0 8.9
Euroscore5+
-
-
Multiple risks 1.2 3.4
Aorta, atheromatous
-
-
Redo/Urgent 3.1 12.0
COPD 0 6
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Appendix P:
OPCAR versus PCI Tree FuIlv Exnanded
91
APPENDIX Q
OPCAE versus PCI Tree with One Markov Heahh State Expanded
I
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Appendix R
Costs for OPCAB versus PCI Model
OPAE 19323 LHSC
(10432 28214)
PCI 11086 LHSC
(5124- 16200)
Acute Post-Operatfve pAF*cAcuteAF + pAngina*cAngïna + pIABP*cIABP +
Complications plnotropes*clnotropes + pMI*cAcuteMl + pRenalFailure*cRf +
pReThoracotomy*cRethoracotomv + pResplnfection*cResplnfection +
pTrans fusecTransfusion + pMediastinitis*cMediastinitis
Myocardial Infarction 8228 Cheng 1996 Taylor
(4114—78481) 2000
Acute NCD 2000 Professional estimate
(1500_2500)
Acute Stroke 13291 Cheng 1996, Sinclair
(6646 — 64768) 2001 Taylor 1990
Angina 1724 OCCP
(800-3500)
Foflow-up 1488 Cheng 2003
(1378— 1598) Lamy 2006
Mediastinitis 36287 Hollenbeak 2000,
(10423 — 28214) Taylor 1990
LateAngina 1724 OCCP
(800-3500)
Post-procedure 1000 Opinion
(500 — 2000)
Reintervention 17170 33% CCAB, 33%
(9000 - 34000) OPCAB, 33% PCI
Respiratory Infection 40717 Cheng 1996
(20359 — 81434) Taylor 1990
Rethoracotomy 4852 Yock 2003
(2426
— 9704)
Transfusion 474 Canadian Blood
(350-55) Services
Post-Stroke 15177 Anis 2006
(7680 — 30720)
AF=atrial fibrillation, C=cost; LHSCLondon Health Sciences Centre (our institution); M1 Myocardial
infarction, NCflneurocognitive dysfunction; p=probabiity
Costs associated with the surgery theatre Urne, supplies (including the stabilizer technology anti disposab]es for
OPCAB), anti length ofstay including overhead costs and depreciation, plus the cost ofprofessional fces paid by the
Ministry of l-Iealth (IVIOH) of Ontario, were included in the cost estimates. ‘Professional fees paid by the MOH were
included
Cost of transfusions was considered relevant only to the health care system (Base Case Analysis) anti societal
perspective since institutions do no pay for blond products directly
Event OPCAB PCI References
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APPENDIX S:
Probabffities and Utifities for OPCAB verstis PCI Model
Death, 30d 0.013 0.004 Cheng 2006
(0.0052 — 0.0281) (0.0001
— 0.015)
Death, 2y 0.034 0.004 Cheng 2006
(0.0388
— 0.0879) (0.0001 — 0.015)
Mediastinitis/Wou 0.035 0.005 Cheng 2006
nd complications, (0.0 146 — 0.0766) (0.0003
— 0.0344)
30d
AMI, 30d 0.030 0.029 Cheng 2006
(0.01 73 — 0.0495) (0.0173 — 0.0477)
AMI, 2y 0.030 0.049 Cheng 2006
Stroke, 30d 0.005 0.003 Cheng 2006
(0.0002
— 0.0206) (0.001 — 0.0148)
Stroke, 2y 0.005 0.011 Cheng 2006
(0.0.0004
— 0.394) (0.0004
— 0.0403)
Angina Recurrence, 0.068 0.138 Cheng 2006
30d (0.0465
— 0.0968) (0.1076 - 0.1757)
Angina Recurrence, 0.128 0.222 Cheng 2006
(0.0926
— 0.1736) (0.1759
— 0.2756)
Reintervention, 30d 0.023 0.033 Cheng 2006
(0.0126
— 0.041 8) (0.0203 — 0.0524)
Remterventîon, 2y 0.037 0.134 Cheng 2006
(0.01 87— 0.0707) (0.0965 — 0.184)
Age 59 Cheng 2006
(50—75)
Years 20
(2 — 20)
Discount 0.03 Garber 1996
(0 — 0.05) CADTH 2006
PreProcedure 0.73 Puskas 2004
QALY (0.5—0.90)
PostProcedureQAL 0.8
Y (0.6—0.1)
Angina 0.73 Puskas 2004
(0.60
— 0.90)
Stroke 0.5 Sinclair 2001
(0
— 0.90) Anis 2006
Event OPCAB PCI References
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APPENDIX T
ICER ScATTERPL0T 0F Oc VERSUS Cc
ICE Scatterpiot of
OPCAB vs. CCAB
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APPENDIX U:
ICER ScATTERPL0T 0F Oc VERSUS PcI
ICE Scatterpiot of
OPCAB vs. PCI
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